id	sid	tid	token	lemma	pos
cord-326672-0x2pe9qd	1	1	key	key	JJ
cord-326672-0x2pe9qd	1	2	:	:	:
cord-326672-0x2pe9qd	1	3	cord-326672	cord-326672	NNP
cord-326672-0x2pe9qd	1	4	-	-	HYPH
cord-326672-0x2pe9qd	1	5	0x2pe9qd	0x2pe9qd	CD
cord-326672-0x2pe9qd	1	6	authors	author	NNS
cord-326672-0x2pe9qd	1	7	:	:	:
cord-326672-0x2pe9qd	1	8	Wainwright	Wainwright	NNP
cord-326672-0x2pe9qd	1	9	,	,	,
cord-326672-0x2pe9qd	1	10	Claire	Claire	NNP
cord-326672-0x2pe9qd	1	11	E	e	NN
cord-326672-0x2pe9qd	1	12	title	title	NN
cord-326672-0x2pe9qd	1	13	:	:	:
cord-326672-0x2pe9qd	1	14	New	new	JJ
cord-326672-0x2pe9qd	1	15	therapies	therapy	NNS
cord-326672-0x2pe9qd	1	16	for	for	IN
cord-326672-0x2pe9qd	1	17	people	people	NNS
cord-326672-0x2pe9qd	1	18	with	with	IN
cord-326672-0x2pe9qd	1	19	CF	CF	NNP
cord-326672-0x2pe9qd	1	20	in	in	IN
cord-326672-0x2pe9qd	1	21	the	the	DT
cord-326672-0x2pe9qd	1	22	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	1	23	modulator	modulator	NN
cord-326672-0x2pe9qd	1	24	world	world	NN
cord-326672-0x2pe9qd	1	25	date	date	NN
cord-326672-0x2pe9qd	1	26	:	:	:
cord-326672-0x2pe9qd	1	27	2020	2020	CD
cord-326672-0x2pe9qd	1	28	-	-	HYPH
cord-326672-0x2pe9qd	1	29	08	08	CD
cord-326672-0x2pe9qd	1	30	-	-	SYM
cord-326672-0x2pe9qd	1	31	10	10	CD
cord-326672-0x2pe9qd	1	32	journal	journal	NN
cord-326672-0x2pe9qd	1	33	:	:	:
cord-326672-0x2pe9qd	1	34	J	J	NNP
cord-326672-0x2pe9qd	1	35	Cyst	Cyst	NNP
cord-326672-0x2pe9qd	1	36	Fibros	Fibros	NNP
cord-326672-0x2pe9qd	1	37	DOI	DOI	NNP
cord-326672-0x2pe9qd	1	38	:	:	:
cord-326672-0x2pe9qd	1	39	10.1016/	10.1016/	CD
cord-326672-0x2pe9qd	2	1	j.jcf.2020.07.019	j.jcf.2020.07.019	NNP
cord-326672-0x2pe9qd	2	2	sha	sha	NNP
cord-326672-0x2pe9qd	2	3	:	:	:
cord-326672-0x2pe9qd	2	4	26c0a06261d8a3581dd7fc8fa29ecce9bad91131	26c0a06261d8a3581dd7fc8fa29ecce9bad91131	CD
cord-326672-0x2pe9qd	2	5	doc_id	doc_id	CD
cord-326672-0x2pe9qd	2	6	:	:	:
cord-326672-0x2pe9qd	2	7	326672	326672	CD
cord-326672-0x2pe9qd	2	8	cord_uid	cord_uid	NNS
cord-326672-0x2pe9qd	2	9	:	:	:
cord-326672-0x2pe9qd	2	10	0x2pe9qd	0x2pe9qd	CD
cord-326672-0x2pe9qd	3	1	nan	nan	NNP
cord-326672-0x2pe9qd	3	2	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	3	3	modulation	modulation	NN
cord-326672-0x2pe9qd	3	4	has	have	VBZ
cord-326672-0x2pe9qd	3	5	led	lead	VBN
cord-326672-0x2pe9qd	3	6	to	to	IN
cord-326672-0x2pe9qd	3	7	improved	improve	VBN
cord-326672-0x2pe9qd	3	8	health	health	NN
cord-326672-0x2pe9qd	3	9	outcomes	outcome	NNS
cord-326672-0x2pe9qd	3	10	for	for	IN
cord-326672-0x2pe9qd	3	11	patients	patient	NNS
cord-326672-0x2pe9qd	3	12	with	with	IN
cord-326672-0x2pe9qd	3	13	CF	CF	NNP
cord-326672-0x2pe9qd	3	14	,	,	,
cord-326672-0x2pe9qd	3	15	although	although	IN
cord-326672-0x2pe9qd	3	16	the	the	DT
cord-326672-0x2pe9qd	3	17	benefits	benefit	NNS
cord-326672-0x2pe9qd	3	18	derived	derive	VBN
cord-326672-0x2pe9qd	3	19	from	from	IN
cord-326672-0x2pe9qd	3	20	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	3	21	modulation	modulation	NN
cord-326672-0x2pe9qd	3	22	have	have	VBP
cord-326672-0x2pe9qd	3	23	also	also	RB
cord-326672-0x2pe9qd	3	24	led	lead	VBN
cord-326672-0x2pe9qd	3	25	to	to	IN
cord-326672-0x2pe9qd	3	26	difficulties	difficulty	NNS
cord-326672-0x2pe9qd	3	27	in	in	IN
cord-326672-0x2pe9qd	3	28	the	the	DT
cord-326672-0x2pe9qd	3	29	design	design	NN
cord-326672-0x2pe9qd	3	30	of	of	IN
cord-326672-0x2pe9qd	3	31	clinical	clinical	JJ
cord-326672-0x2pe9qd	3	32	trials	trial	NNS
cord-326672-0x2pe9qd	3	33	for	for	IN
cord-326672-0x2pe9qd	3	34	new	new	JJ
cord-326672-0x2pe9qd	3	35	medicines	medicine	NNS
cord-326672-0x2pe9qd	3	36	.	.	.
cord-326672-0x2pe9qd	4	1	Established	establish	VBN
cord-326672-0x2pe9qd	4	2	trial	trial	NN
cord-326672-0x2pe9qd	4	3	endpoints	endpoint	NNS
cord-326672-0x2pe9qd	4	4	may	may	MD
cord-326672-0x2pe9qd	4	5	not	not	RB
cord-326672-0x2pe9qd	4	6	be	be	VB
cord-326672-0x2pe9qd	4	7	as	as	RB
cord-326672-0x2pe9qd	4	8	sensitive	sensitive	JJ
cord-326672-0x2pe9qd	4	9	to	to	TO
cord-326672-0x2pe9qd	4	10	change	change	VB
cord-326672-0x2pe9qd	4	11	in	in	IN
cord-326672-0x2pe9qd	4	12	healthier	healthy	JJR
cord-326672-0x2pe9qd	4	13	populations	population	NNS
cord-326672-0x2pe9qd	4	14	,	,	,
cord-326672-0x2pe9qd	4	15	and	and	CC
cord-326672-0x2pe9qd	4	16	new	new	JJ
cord-326672-0x2pe9qd	4	17	outcomes	outcome	NNS
cord-326672-0x2pe9qd	4	18	or	or	CC
cord-326672-0x2pe9qd	4	19	biomarkers	biomarker	NNS
cord-326672-0x2pe9qd	4	20	may	may	MD
cord-326672-0x2pe9qd	4	21	be	be	VB
cord-326672-0x2pe9qd	4	22	required	require	VBN
cord-326672-0x2pe9qd	4	23	.	.	.
cord-326672-0x2pe9qd	5	1	Patients	patient	NNS
cord-326672-0x2pe9qd	5	2	may	may	MD
cord-326672-0x2pe9qd	5	3	be	be	VB
cord-326672-0x2pe9qd	5	4	less	less	RBR
cord-326672-0x2pe9qd	5	5	inclined	inclined	JJ
cord-326672-0x2pe9qd	5	6	to	to	TO
cord-326672-0x2pe9qd	5	7	stop	stop	VB
cord-326672-0x2pe9qd	5	8	effective	effective	JJ
cord-326672-0x2pe9qd	5	9	treatment	treatment	NN
cord-326672-0x2pe9qd	5	10	for	for	IN
cord-326672-0x2pe9qd	5	11	clinical	clinical	JJ
cord-326672-0x2pe9qd	5	12	trials	trial	NNS
cord-326672-0x2pe9qd	5	13	,	,	,
cord-326672-0x2pe9qd	5	14	and	and	CC
cord-326672-0x2pe9qd	5	15	this	this	DT
cord-326672-0x2pe9qd	5	16	makes	make	VBZ
cord-326672-0x2pe9qd	5	17	gold	gold	JJ
cord-326672-0x2pe9qd	5	18	standard	standard	JJ
cord-326672-0x2pe9qd	5	19	placebo	placebo	NN
cord-326672-0x2pe9qd	5	20	-	-	HYPH
cord-326672-0x2pe9qd	5	21	controlled	control	VBN
cord-326672-0x2pe9qd	5	22	trials	trial	NNS
cord-326672-0x2pe9qd	5	23	more	more	RBR
cord-326672-0x2pe9qd	5	24	challenging	challenging	JJ
cord-326672-0x2pe9qd	5	25	.	.	.
cord-326672-0x2pe9qd	6	1	De	De	NNP
cord-326672-0x2pe9qd	6	2	Boeck	Boeck	NNP
cord-326672-0x2pe9qd	6	3	et	et	NNP
cord-326672-0x2pe9qd	6	4	al	al	NNP
cord-326672-0x2pe9qd	6	5	.	.	NNP
cord-326672-0x2pe9qd	6	6	provides	provide	VBZ
cord-326672-0x2pe9qd	6	7	the	the	DT
cord-326672-0x2pe9qd	6	8	summary	summary	NN
cord-326672-0x2pe9qd	6	9	of	of	IN
cord-326672-0x2pe9qd	6	10	discussions	discussion	NNS
cord-326672-0x2pe9qd	6	11	from	from	IN
cord-326672-0x2pe9qd	6	12	a	a	DT
cord-326672-0x2pe9qd	6	13	workshop	workshop	NN
cord-326672-0x2pe9qd	6	14	held	hold	VBN
cord-326672-0x2pe9qd	6	15	in	in	IN
cord-326672-0x2pe9qd	6	16	November	November	NNP
cord-326672-0x2pe9qd	6	17	2019	2019	CD
cord-326672-0x2pe9qd	6	18	that	that	WDT
cord-326672-0x2pe9qd	6	19	focused	focus	VBD
cord-326672-0x2pe9qd	6	20	on	on	IN
cord-326672-0x2pe9qd	6	21	drug	drug	NN
cord-326672-0x2pe9qd	6	22	trial	trial	NN
cord-326672-0x2pe9qd	6	23	design	design	NN
cord-326672-0x2pe9qd	6	24	in	in	IN
cord-326672-0x2pe9qd	6	25	the	the	DT
cord-326672-0x2pe9qd	6	26	new	new	JJ
cord-326672-0x2pe9qd	6	27	era	era	NN
cord-326672-0x2pe9qd	6	28	of	of	IN
cord-326672-0x2pe9qd	6	29	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	6	30	modulation	modulation	NN
cord-326672-0x2pe9qd	6	31	.	.	.
cord-326672-0x2pe9qd	7	1	The	the	DT
cord-326672-0x2pe9qd	7	2	workshop	workshop	NN
cord-326672-0x2pe9qd	7	3	included	include	VBD
cord-326672-0x2pe9qd	7	4	invited	invite	VBN
cord-326672-0x2pe9qd	7	5	clinical	clinical	JJ
cord-326672-0x2pe9qd	7	6	experts	expert	NNS
cord-326672-0x2pe9qd	7	7	as	as	RB
cord-326672-0x2pe9qd	7	8	well	well	RB
cord-326672-0x2pe9qd	7	9	as	as	IN
cord-326672-0x2pe9qd	7	10	representatives	representative	NNS
cord-326672-0x2pe9qd	7	11	from	from	IN
cord-326672-0x2pe9qd	7	12	pharmaceutical	pharmaceutical	JJ
cord-326672-0x2pe9qd	7	13	companies	company	NNS
cord-326672-0x2pe9qd	7	14	,	,	,
cord-326672-0x2pe9qd	7	15	the	the	DT
cord-326672-0x2pe9qd	7	16	European	European	NNP
cord-326672-0x2pe9qd	7	17	Medicines	Medicines	NNPS
cord-326672-0x2pe9qd	7	18	Agency	Agency	NNP
cord-326672-0x2pe9qd	7	19	(	(	-LRB-
cord-326672-0x2pe9qd	7	20	EMA	EMA	NNP
cord-326672-0x2pe9qd	7	21	)	)	-RRB-
cord-326672-0x2pe9qd	7	22	,	,	,
cord-326672-0x2pe9qd	7	23	experts	expert	NNS
cord-326672-0x2pe9qd	7	24	in	in	IN
cord-326672-0x2pe9qd	7	25	Health	Health	NNP
cord-326672-0x2pe9qd	7	26	Technology	Technology	NNP
cord-326672-0x2pe9qd	7	27	Assessment	Assessment	NNP
cord-326672-0x2pe9qd	7	28	and	and	CC
cord-326672-0x2pe9qd	7	29	patient	patient	JJ
cord-326672-0x2pe9qd	7	30	organisations	organisation	NNS
cord-326672-0x2pe9qd	7	31	[	[	-LRB-
cord-326672-0x2pe9qd	7	32	1	1	CD
cord-326672-0x2pe9qd	7	33	]	]	-RRB-
cord-326672-0x2pe9qd	7	34	.	.	.
cord-326672-0x2pe9qd	8	1	There	there	EX
cord-326672-0x2pe9qd	8	2	were	be	VBD
cord-326672-0x2pe9qd	8	3	welcome	welcome	JJ
cord-326672-0x2pe9qd	8	4	discussions	discussion	NNS
cord-326672-0x2pe9qd	8	5	on	on	IN
cord-326672-0x2pe9qd	8	6	trials	trial	NNS
cord-326672-0x2pe9qd	8	7	and	and	CC
cord-326672-0x2pe9qd	8	8	approaches	approach	NNS
cord-326672-0x2pe9qd	8	9	to	to	IN
cord-326672-0x2pe9qd	8	10	drug	drug	NN
cord-326672-0x2pe9qd	8	11	development	development	NN
cord-326672-0x2pe9qd	8	12	for	for	IN
cord-326672-0x2pe9qd	8	13	groups	group	NNS
cord-326672-0x2pe9qd	8	14	such	such	JJ
cord-326672-0x2pe9qd	8	15	as	as	IN
cord-326672-0x2pe9qd	8	16	those	those	DT
cord-326672-0x2pe9qd	8	17	with	with	IN
cord-326672-0x2pe9qd	8	18	rare	rare	JJ
cord-326672-0x2pe9qd	8	19	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	8	20	mutations	mutation	NNS
cord-326672-0x2pe9qd	8	21	and	and	CC
cord-326672-0x2pe9qd	8	22	vulnerable	vulnerable	JJ
cord-326672-0x2pe9qd	8	23	groups	group	NNS
cord-326672-0x2pe9qd	8	24	such	such	JJ
cord-326672-0x2pe9qd	8	25	as	as	IN
cord-326672-0x2pe9qd	8	26	infants	infant	NNS
cord-326672-0x2pe9qd	8	27	and	and	CC
cord-326672-0x2pe9qd	8	28	young	young	JJ
cord-326672-0x2pe9qd	8	29	children	child	NNS
cord-326672-0x2pe9qd	8	30	.	.	.
cord-326672-0x2pe9qd	9	1	Infants	infant	NNS
cord-326672-0x2pe9qd	9	2	and	and	CC
cord-326672-0x2pe9qd	9	3	young	young	JJ
cord-326672-0x2pe9qd	9	4	children	child	NNS
cord-326672-0x2pe9qd	9	5	require	require	VBP
cord-326672-0x2pe9qd	9	6	special	special	JJ
cord-326672-0x2pe9qd	9	7	consideration	consideration	NN
cord-326672-0x2pe9qd	9	8	as	as	IN
cord-326672-0x2pe9qd	9	9	they	-PRON-	PRP
cord-326672-0x2pe9qd	9	10	may	may	MD
cord-326672-0x2pe9qd	9	11	derive	derive	VB
cord-326672-0x2pe9qd	9	12	the	the	DT
cord-326672-0x2pe9qd	9	13	greatest	great	JJS
cord-326672-0x2pe9qd	9	14	benefit	benefit	NN
cord-326672-0x2pe9qd	9	15	in	in	IN
cord-326672-0x2pe9qd	9	16	the	the	DT
cord-326672-0x2pe9qd	9	17	long	long	JJ
cord-326672-0x2pe9qd	9	18	term	term	NN
cord-326672-0x2pe9qd	9	19	from	from	IN
cord-326672-0x2pe9qd	9	20	early	early	JJ
cord-326672-0x2pe9qd	9	21	improvement	improvement	NN
cord-326672-0x2pe9qd	9	22	of	of	IN
cord-326672-0x2pe9qd	9	23	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	9	24	function	function	NN
cord-326672-0x2pe9qd	9	25	,	,	,
cord-326672-0x2pe9qd	9	26	although	although	IN
cord-326672-0x2pe9qd	9	27	early	early	JJ
cord-326672-0x2pe9qd	9	28	exposure	exposure	NN
cord-326672-0x2pe9qd	9	29	may	may	MD
cord-326672-0x2pe9qd	9	30	also	also	RB
cord-326672-0x2pe9qd	9	31	increase	increase	VB
cord-326672-0x2pe9qd	9	32	the	the	DT
cord-326672-0x2pe9qd	9	33	potential	potential	NN
cord-326672-0x2pe9qd	9	34	for	for	IN
cord-326672-0x2pe9qd	9	35	greater	great	JJR
cord-326672-0x2pe9qd	9	36	harm	harm	NN
cord-326672-0x2pe9qd	9	37	given	give	VBN
cord-326672-0x2pe9qd	9	38	the	the	DT
cord-326672-0x2pe9qd	9	39	developmental	developmental	JJ
cord-326672-0x2pe9qd	9	40	context	context	NN
cord-326672-0x2pe9qd	9	41	.	.	.
cord-326672-0x2pe9qd	10	1	Measuring	measure	VBG
cord-326672-0x2pe9qd	10	2	efficacy	efficacy	NN
cord-326672-0x2pe9qd	10	3	in	in	IN
cord-326672-0x2pe9qd	10	4	uncooperative	uncooperative	JJ
cord-326672-0x2pe9qd	10	5	young	young	JJ
cord-326672-0x2pe9qd	10	6	children	child	NNS
cord-326672-0x2pe9qd	10	7	also	also	RB
cord-326672-0x2pe9qd	10	8	presents	present	VBZ
cord-326672-0x2pe9qd	10	9	many	many	JJ
cord-326672-0x2pe9qd	10	10	challenges	challenge	NNS
cord-326672-0x2pe9qd	10	11	,	,	,
cord-326672-0x2pe9qd	10	12	and	and	CC
cord-326672-0x2pe9qd	10	13	there	there	EX
cord-326672-0x2pe9qd	10	14	are	be	VBP
cord-326672-0x2pe9qd	10	15	time	time	NN
cord-326672-0x2pe9qd	10	16	constraints	constraint	NNS
cord-326672-0x2pe9qd	10	17	to	to	IN
cord-326672-0x2pe9qd	10	18	understanding	understand	VBG
cord-326672-0x2pe9qd	10	19	longitudinal	longitudinal	JJ
cord-326672-0x2pe9qd	10	20	safety	safety	NN
cord-326672-0x2pe9qd	10	21	and	and	CC
cord-326672-0x2pe9qd	10	22	outcomes	outcome	NNS
cord-326672-0x2pe9qd	10	23	.	.	.
cord-326672-0x2pe9qd	11	1	Regulatory	regulatory	JJ
cord-326672-0x2pe9qd	11	2	requirements	requirement	NNS
cord-326672-0x2pe9qd	11	3	for	for	IN
cord-326672-0x2pe9qd	11	4	drug	drug	NN
cord-326672-0x2pe9qd	11	5	development	development	NN
cord-326672-0x2pe9qd	11	6	vary	vary	VBP
cord-326672-0x2pe9qd	11	7	between	between	IN
cord-326672-0x2pe9qd	11	8	different	different	JJ
cord-326672-0x2pe9qd	11	9	countries	country	NNS
cord-326672-0x2pe9qd	11	10	.	.	.
cord-326672-0x2pe9qd	12	1	These	these	DT
cord-326672-0x2pe9qd	12	2	differences	difference	NNS
cord-326672-0x2pe9qd	12	3	lead	lead	VBP
cord-326672-0x2pe9qd	12	4	to	to	IN
cord-326672-0x2pe9qd	12	5	barriers	barrier	NNS
cord-326672-0x2pe9qd	12	6	for	for	IN
cord-326672-0x2pe9qd	12	7	drug	drug	NN
cord-326672-0x2pe9qd	12	8	development	development	NN
cord-326672-0x2pe9qd	12	9	and	and	CC
cord-326672-0x2pe9qd	12	10	contribute	contribute	VB
cord-326672-0x2pe9qd	12	11	to	to	IN
cord-326672-0x2pe9qd	12	12	reduced	reduce	VBN
cord-326672-0x2pe9qd	12	13	global	global	JJ
cord-326672-0x2pe9qd	12	14	access	access	NN
cord-326672-0x2pe9qd	12	15	and	and	CC
cord-326672-0x2pe9qd	12	16	increased	increase	VBN
cord-326672-0x2pe9qd	12	17	costs	cost	NNS
cord-326672-0x2pe9qd	12	18	associated	associate	VBN
cord-326672-0x2pe9qd	12	19	with	with	IN
cord-326672-0x2pe9qd	12	20	drug	drug	NN
cord-326672-0x2pe9qd	12	21	development	development	NN
cord-326672-0x2pe9qd	12	22	.	.	.
cord-326672-0x2pe9qd	13	1	Harmonization	harmonization	NN
cord-326672-0x2pe9qd	13	2	between	between	IN
cord-326672-0x2pe9qd	13	3	regulatory	regulatory	JJ
cord-326672-0x2pe9qd	13	4	authorities	authority	NNS
cord-326672-0x2pe9qd	13	5	should	should	MD
cord-326672-0x2pe9qd	13	6	provide	provide	VB
cord-326672-0x2pe9qd	13	7	agreement	agreement	NN
cord-326672-0x2pe9qd	13	8	on	on	IN
cord-326672-0x2pe9qd	13	9	the	the	DT
cord-326672-0x2pe9qd	13	10	technical	technical	JJ
cord-326672-0x2pe9qd	13	11	and	and	CC
cord-326672-0x2pe9qd	13	12	marketing	marketing	NN
cord-326672-0x2pe9qd	13	13	requirements	requirement	NNS
cord-326672-0x2pe9qd	13	14	for	for	IN
cord-326672-0x2pe9qd	13	15	therapeutic	therapeutic	JJ
cord-326672-0x2pe9qd	13	16	products	product	NNS
cord-326672-0x2pe9qd	13	17	.	.	.
cord-326672-0x2pe9qd	14	1	This	this	DT
cord-326672-0x2pe9qd	14	2	requires	require	VBZ
cord-326672-0x2pe9qd	14	3	cooperation	cooperation	NN
cord-326672-0x2pe9qd	14	4	between	between	IN
cord-326672-0x2pe9qd	14	5	the	the	DT
cord-326672-0x2pe9qd	14	6	regulatory	regulatory	JJ
cord-326672-0x2pe9qd	14	7	authorities	authority	NNS
cord-326672-0x2pe9qd	14	8	working	work	VBG
cord-326672-0x2pe9qd	14	9	with	with	IN
cord-326672-0x2pe9qd	14	10	pharmaceutical	pharmaceutical	JJ
cord-326672-0x2pe9qd	14	11	companies	company	NNS
cord-326672-0x2pe9qd	14	12	to	to	TO
cord-326672-0x2pe9qd	14	13	achieve	achieve	VB
cord-326672-0x2pe9qd	14	14	an	an	DT
cord-326672-0x2pe9qd	14	15	agreed	agree	VBN
cord-326672-0x2pe9qd	14	16	pathway	pathway	NN
cord-326672-0x2pe9qd	14	17	for	for	IN
cord-326672-0x2pe9qd	14	18	the	the	DT
cord-326672-0x2pe9qd	14	19	ethical	ethical	JJ
cord-326672-0x2pe9qd	14	20	development	development	NN
cord-326672-0x2pe9qd	14	21	of	of	IN
cord-326672-0x2pe9qd	14	22	new	new	JJ
cord-326672-0x2pe9qd	14	23	therapies	therapy	NNS
cord-326672-0x2pe9qd	14	24	and	and	CC
cord-326672-0x2pe9qd	14	25	reduce	reduce	VB
cord-326672-0x2pe9qd	14	26	both	both	DT
cord-326672-0x2pe9qd	14	27	duplication	duplication	NN
cord-326672-0x2pe9qd	14	28	of	of	IN
cord-326672-0x2pe9qd	14	29	effort	effort	NN
cord-326672-0x2pe9qd	14	30	,	,	,
cord-326672-0x2pe9qd	14	31	and	and	CC
cord-326672-0x2pe9qd	14	32	the	the	DT
cord-326672-0x2pe9qd	14	33	time	time	NN
cord-326672-0x2pe9qd	14	34	taken	take	VBN
cord-326672-0x2pe9qd	14	35	to	to	TO
cord-326672-0x2pe9qd	14	36	bring	bring	VB
cord-326672-0x2pe9qd	14	37	a	a	DT
cord-326672-0x2pe9qd	14	38	product	product	NN
cord-326672-0x2pe9qd	14	39	from	from	IN
cord-326672-0x2pe9qd	14	40	bench	bench	NN
cord-326672-0x2pe9qd	14	41	to	to	IN
cord-326672-0x2pe9qd	14	42	bedside	bedside	NN
cord-326672-0x2pe9qd	14	43	across	across	IN
cord-326672-0x2pe9qd	14	44	different	different	JJ
cord-326672-0x2pe9qd	14	45	jurisdictions	jurisdiction	NNS
cord-326672-0x2pe9qd	14	46	.	.	.
cord-326672-0x2pe9qd	15	1	Globally	globally	RB
cord-326672-0x2pe9qd	15	2	there	there	EX
cord-326672-0x2pe9qd	15	3	are	be	VBP
cord-326672-0x2pe9qd	15	4	those	those	DT
cord-326672-0x2pe9qd	15	5	who	who	WP
cord-326672-0x2pe9qd	15	6	are	be	VBP
cord-326672-0x2pe9qd	15	7	living	live	VBG
cord-326672-0x2pe9qd	15	8	without	without	IN
cord-326672-0x2pe9qd	15	9	access	access	NN
cord-326672-0x2pe9qd	15	10	to	to	IN
cord-326672-0x2pe9qd	15	11	new	new	JJ
cord-326672-0x2pe9qd	15	12	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	15	13	modulation	modulation	NN
cord-326672-0x2pe9qd	15	14	,	,	,
cord-326672-0x2pe9qd	15	15	or	or	CC
cord-326672-0x2pe9qd	15	16	other	other	JJ
cord-326672-0x2pe9qd	15	17	new	new	JJ
cord-326672-0x2pe9qd	15	18	medicines	medicine	NNS
cord-326672-0x2pe9qd	15	19	,	,	,
cord-326672-0x2pe9qd	15	20	because	because	IN
cord-326672-0x2pe9qd	15	21	of	of	IN
cord-326672-0x2pe9qd	15	22	regulatory	regulatory	JJ
cord-326672-0x2pe9qd	15	23	issues	issue	NNS
cord-326672-0x2pe9qd	15	24	as	as	RB
cord-326672-0x2pe9qd	15	25	well	well	RB
cord-326672-0x2pe9qd	15	26	as	as	IN
cord-326672-0x2pe9qd	15	27	the	the	DT
cord-326672-0x2pe9qd	15	28	cost	cost	NN
cord-326672-0x2pe9qd	15	29	of	of	IN
cord-326672-0x2pe9qd	15	30	these	these	DT
cord-326672-0x2pe9qd	15	31	expensive	expensive	JJ
cord-326672-0x2pe9qd	15	32	treatments	treatment	NNS
cord-326672-0x2pe9qd	15	33	.	.	.
cord-326672-0x2pe9qd	16	1	Mayer	Mayer	NNP
cord-326672-0x2pe9qd	16	2	-	-	HYPH
cord-326672-0x2pe9qd	16	3	Hamblett	Hamblett	NNP
cord-326672-0x2pe9qd	16	4	et	et	NNP
cord-326672-0x2pe9qd	16	5	al	al	NNP
cord-326672-0x2pe9qd	16	6	.	.	.
cord-326672-0x2pe9qd	17	1	reflect	reflect	VB
cord-326672-0x2pe9qd	17	2	the	the	DT
cord-326672-0x2pe9qd	17	3	discussions	discussion	NNS
cord-326672-0x2pe9qd	17	4	and	and	CC
cord-326672-0x2pe9qd	17	5	outcomes	outcome	NNS
cord-326672-0x2pe9qd	17	6	from	from	IN
cord-326672-0x2pe9qd	17	7	a	a	DT
cord-326672-0x2pe9qd	17	8	workshop	workshop	NN
cord-326672-0x2pe9qd	17	9	of	of	IN
cord-326672-0x2pe9qd	17	10	invited	invite	VBN
cord-326672-0x2pe9qd	17	11	international	international	JJ
cord-326672-0x2pe9qd	17	12	experts	expert	NNS
cord-326672-0x2pe9qd	17	13	on	on	IN
cord-326672-0x2pe9qd	17	14	clinical	clinical	JJ
cord-326672-0x2pe9qd	17	15	trials	trial	NNS
cord-326672-0x2pe9qd	17	16	and	and	CC
cord-326672-0x2pe9qd	17	17	trial	trial	NN
cord-326672-0x2pe9qd	17	18	networks	network	NNS
cord-326672-0x2pe9qd	17	19	that	that	WDT
cord-326672-0x2pe9qd	17	20	was	be	VBD
cord-326672-0x2pe9qd	17	21	held	hold	VBN
cord-326672-0x2pe9qd	17	22	in	in	IN
cord-326672-0x2pe9qd	17	23	October	October	NNP
cord-326672-0x2pe9qd	17	24	2019	2019	CD
cord-326672-0x2pe9qd	17	25	associated	associate	VBN
cord-326672-0x2pe9qd	17	26	with	with	IN
cord-326672-0x2pe9qd	17	27	the	the	DT
cord-326672-0x2pe9qd	17	28	North	North	NNP
cord-326672-0x2pe9qd	17	29	American	American	NNP
cord-326672-0x2pe9qd	17	30	CF	CF	NNP
cord-326672-0x2pe9qd	17	31	meeting	meeting	NN
cord-326672-0x2pe9qd	17	32	[	[	-LRB-
cord-326672-0x2pe9qd	17	33	2	2	CD
cord-326672-0x2pe9qd	17	34	]	]	-RRB-
cord-326672-0x2pe9qd	17	35	.	.	.
cord-326672-0x2pe9qd	18	1	The	the	DT
cord-326672-0x2pe9qd	18	2	workshop	workshop	NN
cord-326672-0x2pe9qd	18	3	focused	focus	VBD
cord-326672-0x2pe9qd	18	4	on	on	IN
cord-326672-0x2pe9qd	18	5	the	the	DT
cord-326672-0x2pe9qd	18	6	development	development	NN
cord-326672-0x2pe9qd	18	7	of	of	IN
cord-326672-0x2pe9qd	18	8	new	new	JJ
cord-326672-0x2pe9qd	18	9	therapies	therapy	NNS
cord-326672-0x2pe9qd	18	10	for	for	IN
cord-326672-0x2pe9qd	18	11	CF	CF	NNP
cord-326672-0x2pe9qd	18	12	and	and	CC
cord-326672-0x2pe9qd	18	13	discussed	discuss	VBD
cord-326672-0x2pe9qd	18	14	the	the	DT
cord-326672-0x2pe9qd	18	15	challenges	challenge	NNS
cord-326672-0x2pe9qd	18	16	and	and	CC
cord-326672-0x2pe9qd	18	17	approaches	approach	NNS
cord-326672-0x2pe9qd	18	18	to	to	IN
cord-326672-0x2pe9qd	18	19	regulatory	regulatory	JJ
cord-326672-0x2pe9qd	18	20	requirements	requirement	NNS
cord-326672-0x2pe9qd	18	21	in	in	IN
cord-326672-0x2pe9qd	18	22	the	the	DT
cord-326672-0x2pe9qd	18	23	post	post	NN
cord-326672-0x2pe9qd	18	24	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	18	25	modulator	modulator	NN
cord-326672-0x2pe9qd	18	26	environment	environment	NN
cord-326672-0x2pe9qd	18	27	including	include	VBG
cord-326672-0x2pe9qd	18	28	treatments	treatment	NNS
cord-326672-0x2pe9qd	18	29	for	for	IN
cord-326672-0x2pe9qd	18	30	rare	rare	JJ
cord-326672-0x2pe9qd	18	31	mutations	mutation	NNS
cord-326672-0x2pe9qd	18	32	.	.	.
cord-326672-0x2pe9qd	19	1	The	the	DT
cord-326672-0x2pe9qd	19	2	workshop	workshop	NN
cord-326672-0x2pe9qd	19	3	highlighted	highlight	VBD
cord-326672-0x2pe9qd	19	4	the	the	DT
cord-326672-0x2pe9qd	19	5	crucial	crucial	JJ
cord-326672-0x2pe9qd	19	6	importance	importance	NN
cord-326672-0x2pe9qd	19	7	of	of	IN
cord-326672-0x2pe9qd	19	8	clear	clear	JJ
cord-326672-0x2pe9qd	19	9	communication	communication	NN
cord-326672-0x2pe9qd	19	10	between	between	IN
cord-326672-0x2pe9qd	19	11	all	all	DT
cord-326672-0x2pe9qd	19	12	stakeholders	stakeholder	NNS
cord-326672-0x2pe9qd	19	13	.	.	.
cord-326672-0x2pe9qd	20	1	The	the	DT
cord-326672-0x2pe9qd	20	2	workshop	workshop	NN
cord-326672-0x2pe9qd	20	3	also	also	RB
cord-326672-0x2pe9qd	20	4	provided	provide	VBD
cord-326672-0x2pe9qd	20	5	strategies	strategy	NNS
cord-326672-0x2pe9qd	20	6	for	for	IN
cord-326672-0x2pe9qd	20	7	the	the	DT
cord-326672-0x2pe9qd	20	8	development	development	NN
cord-326672-0x2pe9qd	20	9	of	of	IN
cord-326672-0x2pe9qd	20	10	new	new	JJ
cord-326672-0x2pe9qd	20	11	anti	anti	JJ
cord-326672-0x2pe9qd	20	12	-	-	JJ
cord-326672-0x2pe9qd	20	13	infective	infective	JJ
cord-326672-0x2pe9qd	20	14	,	,	,
cord-326672-0x2pe9qd	20	15	anti	anti	JJ
cord-326672-0x2pe9qd	20	16	-	-	JJ
cord-326672-0x2pe9qd	20	17	inflammatory	inflammatory	JJ
cord-326672-0x2pe9qd	20	18	and	and	CC
cord-326672-0x2pe9qd	20	19	other	other	JJ
cord-326672-0x2pe9qd	20	20	symptomatic	symptomatic	JJ
cord-326672-0x2pe9qd	20	21	treatments	treatment	NNS
cord-326672-0x2pe9qd	20	22	,	,	,
cord-326672-0x2pe9qd	20	23	as	as	RB
cord-326672-0x2pe9qd	20	24	well	well	RB
cord-326672-0x2pe9qd	20	25	as	as	IN
cord-326672-0x2pe9qd	20	26	for	for	IN
cord-326672-0x2pe9qd	20	27	the	the	DT
cord-326672-0x2pe9qd	20	28	development	development	NN
cord-326672-0x2pe9qd	20	29	of	of	IN
cord-326672-0x2pe9qd	20	30	new	new	JJ
cord-326672-0x2pe9qd	20	31	cellular	cellular	JJ
cord-326672-0x2pe9qd	20	32	therapies	therapy	NNS
cord-326672-0x2pe9qd	20	33	that	that	WDT
cord-326672-0x2pe9qd	20	34	would	would	MD
cord-326672-0x2pe9qd	20	35	be	be	VB
cord-326672-0x2pe9qd	20	36	impacted	impact	VBN
cord-326672-0x2pe9qd	20	37	by	by	IN
cord-326672-0x2pe9qd	20	38	the	the	DT
cord-326672-0x2pe9qd	20	39	availability	availability	NN
cord-326672-0x2pe9qd	20	40	of	of	IN
cord-326672-0x2pe9qd	20	41	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	20	42	modulation	modulation	NN
cord-326672-0x2pe9qd	20	43	.	.	.
cord-326672-0x2pe9qd	21	1	Regulatory	regulatory	JJ
cord-326672-0x2pe9qd	21	2	authorities	authority	NNS
cord-326672-0x2pe9qd	21	3	have	have	VBP
cord-326672-0x2pe9qd	21	4	started	start	VBN
cord-326672-0x2pe9qd	21	5	to	to	TO
cord-326672-0x2pe9qd	21	6	find	find	VB
cord-326672-0x2pe9qd	21	7	solutions	solution	NNS
cord-326672-0x2pe9qd	21	8	to	to	IN
cord-326672-0x2pe9qd	21	9	some	some	DT
cord-326672-0x2pe9qd	21	10	of	of	IN
cord-326672-0x2pe9qd	21	11	the	the	DT
cord-326672-0x2pe9qd	21	12	challenges	challenge	NNS
cord-326672-0x2pe9qd	21	13	raised	raise	VBN
cord-326672-0x2pe9qd	21	14	in	in	IN
cord-326672-0x2pe9qd	21	15	both	both	CC
cord-326672-0x2pe9qd	21	16	the	the	DT
cord-326672-0x2pe9qd	21	17	workshops	workshop	NNS
cord-326672-0x2pe9qd	21	18	.	.	.
cord-326672-0x2pe9qd	22	1	The	the	DT
cord-326672-0x2pe9qd	22	2	Food	Food	NNP
cord-326672-0x2pe9qd	22	3	and	and	CC
cord-326672-0x2pe9qd	22	4	Drug	Drug	NNP
cord-326672-0x2pe9qd	22	5	Administration	Administration	NNP
cord-326672-0x2pe9qd	22	6	(	(	-LRB-
cord-326672-0x2pe9qd	22	7	FDA	FDA	NNP
cord-326672-0x2pe9qd	22	8	)	)	-RRB-
cord-326672-0x2pe9qd	22	9	in	in	IN
cord-326672-0x2pe9qd	22	10	2017	2017	CD
cord-326672-0x2pe9qd	22	11	took	take	VBD
cord-326672-0x2pe9qd	22	12	the	the	DT
cord-326672-0x2pe9qd	22	13	step	step	NN
cord-326672-0x2pe9qd	22	14	of	of	IN
cord-326672-0x2pe9qd	22	15	approving	approve	VBG
cord-326672-0x2pe9qd	22	16	the	the	DT
cord-326672-0x2pe9qd	22	17	potentiator	potentiator	NN
cord-326672-0x2pe9qd	22	18	ivacaftor	ivacaftor	NN
cord-326672-0x2pe9qd	22	19	for	for	IN
cord-326672-0x2pe9qd	22	20	an	an	DT
cord-326672-0x2pe9qd	22	21	extended	extended	JJ
cord-326672-0x2pe9qd	22	22	list	list	NN
cord-326672-0x2pe9qd	22	23	of	of	IN
cord-326672-0x2pe9qd	22	24	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	22	25	mutations	mutation	NNS
cord-326672-0x2pe9qd	22	26	based	base	VBN
cord-326672-0x2pe9qd	22	27	on	on	IN
cord-326672-0x2pe9qd	22	28	laboratory	laboratory	NN
cord-326672-0x2pe9qd	22	29	studies	study	NNS
cord-326672-0x2pe9qd	22	30	rather	rather	RB
cord-326672-0x2pe9qd	22	31	than	than	IN
cord-326672-0x2pe9qd	22	32	specific	specific	JJ
cord-326672-0x2pe9qd	22	33	clinical	clinical	JJ
cord-326672-0x2pe9qd	22	34	trial	trial	NN
cord-326672-0x2pe9qd	22	35	evidence	evidence	NN
cord-326672-0x2pe9qd	22	36	.	.	.
cord-326672-0x2pe9qd	23	1	The	the	DT
cord-326672-0x2pe9qd	23	2	premise	premise	NN
cord-326672-0x2pe9qd	23	3	for	for	IN
cord-326672-0x2pe9qd	23	4	this	this	DT
cord-326672-0x2pe9qd	23	5	decision	decision	NN
cord-326672-0x2pe9qd	23	6	was	be	VBD
cord-326672-0x2pe9qd	23	7	that	that	IN
cord-326672-0x2pe9qd	23	8	clinical	clinical	JJ
cord-326672-0x2pe9qd	23	9	trials	trial	NNS
cord-326672-0x2pe9qd	23	10	for	for	IN
cord-326672-0x2pe9qd	23	11	many	many	JJ
cord-326672-0x2pe9qd	23	12	rare	rare	JJ
cord-326672-0x2pe9qd	23	13	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	23	14	mutations	mutation	NNS
cord-326672-0x2pe9qd	23	15	would	would	MD
cord-326672-0x2pe9qd	23	16	not	not	RB
cord-326672-0x2pe9qd	23	17	be	be	VB
cord-326672-0x2pe9qd	23	18	feasible	feasible	JJ
cord-326672-0x2pe9qd	23	19	,	,	,
cord-326672-0x2pe9qd	23	20	and	and	CC
cord-326672-0x2pe9qd	23	21	that	that	IN
cord-326672-0x2pe9qd	23	22	cell	cell	NN
cord-326672-0x2pe9qd	23	23	models	model	NNS
cord-326672-0x2pe9qd	23	24	of	of	IN
cord-326672-0x2pe9qd	23	25	functional	functional	JJ
cord-326672-0x2pe9qd	23	26	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	23	27	responses	response	NNS
cord-326672-0x2pe9qd	23	28	were	be	VBD
cord-326672-0x2pe9qd	23	29	generally	generally	RB
cord-326672-0x2pe9qd	23	30	predictive	predictive	JJ
cord-326672-0x2pe9qd	23	31	of	of	IN
cord-326672-0x2pe9qd	23	32	the	the	DT
cord-326672-0x2pe9qd	23	33	clinical	clinical	JJ
cord-326672-0x2pe9qd	23	34	benefits	benefit	NNS
cord-326672-0x2pe9qd	23	35	[	[	-LRB-
cord-326672-0x2pe9qd	23	36	3	3	CD
cord-326672-0x2pe9qd	23	37	]	]	-RRB-
cord-326672-0x2pe9qd	23	38	.	.	.
cord-326672-0x2pe9qd	24	1	This	this	DT
cord-326672-0x2pe9qd	24	2	approach	approach	NN
cord-326672-0x2pe9qd	24	3	will	will	MD
cord-326672-0x2pe9qd	24	4	need	need	VB
cord-326672-0x2pe9qd	24	5	careful	careful	JJ
cord-326672-0x2pe9qd	24	6	consideration	consideration	NN
cord-326672-0x2pe9qd	24	7	and	and	CC
cord-326672-0x2pe9qd	24	8	agreement	agreement	NN
cord-326672-0x2pe9qd	24	9	on	on	IN
cord-326672-0x2pe9qd	24	10	which	which	WDT
cord-326672-0x2pe9qd	24	11	cellular	cellular	JJ
cord-326672-0x2pe9qd	24	12	approaches	approach	NNS
cord-326672-0x2pe9qd	24	13	are	be	VBP
cord-326672-0x2pe9qd	24	14	required	require	VBN
cord-326672-0x2pe9qd	24	15	,	,	,
cord-326672-0x2pe9qd	24	16	and	and	CC
cord-326672-0x2pe9qd	24	17	for	for	IN
cord-326672-0x2pe9qd	24	18	which	which	WDT
cord-326672-0x2pe9qd	24	19	therapies	therapy	NNS
cord-326672-0x2pe9qd	24	20	they	-PRON-	PRP
cord-326672-0x2pe9qd	24	21	are	be	VBP
cord-326672-0x2pe9qd	24	22	appropriate	appropriate	JJ
cord-326672-0x2pe9qd	24	23	in	in	IN
cord-326672-0x2pe9qd	24	24	the	the	DT
cord-326672-0x2pe9qd	24	25	future	future	NN
cord-326672-0x2pe9qd	24	26	,	,	,
cord-326672-0x2pe9qd	24	27	but	but	CC
cord-326672-0x2pe9qd	24	28	this	this	DT
cord-326672-0x2pe9qd	24	29	has	have	VBZ
cord-326672-0x2pe9qd	24	30	certainly	certainly	RB
cord-326672-0x2pe9qd	24	31	opened	open	VBN
cord-326672-0x2pe9qd	24	32	a	a	DT
cord-326672-0x2pe9qd	24	33	new	new	JJ
cord-326672-0x2pe9qd	24	34	door	door	NN
cord-326672-0x2pe9qd	24	35	for	for	IN
cord-326672-0x2pe9qd	24	36	drug	drug	NN
cord-326672-0x2pe9qd	24	37	development	development	NN
cord-326672-0x2pe9qd	24	38	and	and	CC
cord-326672-0x2pe9qd	24	39	regulatory	regulatory	JJ
cord-326672-0x2pe9qd	24	40	approval	approval	NN
cord-326672-0x2pe9qd	24	41	.	.	.
cord-326672-0x2pe9qd	25	1	During	during	IN
cord-326672-0x2pe9qd	25	2	the	the	DT
cord-326672-0x2pe9qd	25	3	peer	peer	NN
cord-326672-0x2pe9qd	25	4	review	review	NN
cord-326672-0x2pe9qd	25	5	process	process	NN
cord-326672-0x2pe9qd	25	6	,	,	,
cord-326672-0x2pe9qd	25	7	an	an	DT
cord-326672-0x2pe9qd	25	8	issue	issue	NN
cord-326672-0x2pe9qd	25	9	arose	arise	VBD
cord-326672-0x2pe9qd	25	10	around	around	IN
cord-326672-0x2pe9qd	25	11	the	the	DT
cord-326672-0x2pe9qd	25	12	terminology	terminology	NN
cord-326672-0x2pe9qd	25	13	used	use	VBN
cord-326672-0x2pe9qd	25	14	in	in	IN
cord-326672-0x2pe9qd	25	15	both	both	DT
cord-326672-0x2pe9qd	25	16	manuscripts	manuscript	NNS
cord-326672-0x2pe9qd	25	17	.	.	.
cord-326672-0x2pe9qd	26	1	This	this	DT
cord-326672-0x2pe9qd	26	2	led	lead	VBD
cord-326672-0x2pe9qd	26	3	to	to	IN
cord-326672-0x2pe9qd	26	4	considerable	considerable	JJ
cord-326672-0x2pe9qd	26	5	debate	debate	NN
cord-326672-0x2pe9qd	26	6	between	between	IN
cord-326672-0x2pe9qd	26	7	the	the	DT
cord-326672-0x2pe9qd	26	8	authors	author	NNS
cord-326672-0x2pe9qd	26	9	,	,	,
cord-326672-0x2pe9qd	26	10	the	the	DT
cord-326672-0x2pe9qd	26	11	reviewers	reviewer	NNS
cord-326672-0x2pe9qd	26	12	and	and	CC
cord-326672-0x2pe9qd	26	13	the	the	DT
cord-326672-0x2pe9qd	26	14	journal	journal	NN
cord-326672-0x2pe9qd	26	15	,	,	,
cord-326672-0x2pe9qd	26	16	and	and	CC
cord-326672-0x2pe9qd	26	17	given	give	VBN
cord-326672-0x2pe9qd	26	18	the	the	DT
cord-326672-0x2pe9qd	26	19	strong	strong	JJ
cord-326672-0x2pe9qd	26	20	opinions	opinion	NNS
cord-326672-0x2pe9qd	26	21	around	around	IN
cord-326672-0x2pe9qd	26	22	the	the	DT
cord-326672-0x2pe9qd	26	23	terminology	terminology	NN
cord-326672-0x2pe9qd	26	24	,	,	,
cord-326672-0x2pe9qd	26	25	it	-PRON-	PRP
cord-326672-0x2pe9qd	26	26	may	may	MD
cord-326672-0x2pe9qd	26	27	be	be	VB
cord-326672-0x2pe9qd	26	28	worthwhile	worthwhile	JJ
cord-326672-0x2pe9qd	26	29	to	to	TO
cord-326672-0x2pe9qd	26	30	reflect	reflect	VB
cord-326672-0x2pe9qd	26	31	on	on	IN
cord-326672-0x2pe9qd	26	32	this	this	DT
cord-326672-0x2pe9qd	26	33	debate	debate	NN
cord-326672-0x2pe9qd	26	34	.	.	.
cord-326672-0x2pe9qd	27	1	Both	both	DT
cord-326672-0x2pe9qd	27	2	manuscripts	manuscript	NNS
cord-326672-0x2pe9qd	27	3	initially	initially	RB
cord-326672-0x2pe9qd	27	4	used	use	VBD
cord-326672-0x2pe9qd	27	5	the	the	DT
cord-326672-0x2pe9qd	27	6	term	term	NN
cord-326672-0x2pe9qd	27	7	"	"	``
cord-326672-0x2pe9qd	27	8	highly	highly	RB
cord-326672-0x2pe9qd	27	9	effective	effective	JJ
cord-326672-0x2pe9qd	27	10	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	27	11	modulators	modulator	NNS
cord-326672-0x2pe9qd	27	12	"	"	''
cord-326672-0x2pe9qd	27	13	to	to	TO
cord-326672-0x2pe9qd	27	14	identify	identify	VB
cord-326672-0x2pe9qd	27	15	the	the	DT
cord-326672-0x2pe9qd	27	16	exceptional	exceptional	JJ
cord-326672-0x2pe9qd	27	17	outcomes	outcome	NNS
cord-326672-0x2pe9qd	27	18	from	from	IN
cord-326672-0x2pe9qd	27	19	two	two	CD
cord-326672-0x2pe9qd	27	20	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	27	21	modulators	modulator	NNS
cord-326672-0x2pe9qd	27	22	currently	currently	RB
cord-326672-0x2pe9qd	27	23	in	in	IN
cord-326672-0x2pe9qd	27	24	clinical	clinical	JJ
cord-326672-0x2pe9qd	27	25	use	use	NN
cord-326672-0x2pe9qd	27	26	.	.	.
cord-326672-0x2pe9qd	28	1	The	the	DT
cord-326672-0x2pe9qd	28	2	two	two	CD
cord-326672-0x2pe9qd	28	3	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	28	4	modulators	modulator	NNS
cord-326672-0x2pe9qd	28	5	include	include	VBP
cord-326672-0x2pe9qd	28	6	ivacaftor	ivacaftor	NN
cord-326672-0x2pe9qd	28	7	in	in	IN
cord-326672-0x2pe9qd	28	8	patients	patient	NNS
cord-326672-0x2pe9qd	28	9	with	with	IN
cord-326672-0x2pe9qd	28	10	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	28	11	gating	gating	NN
cord-326672-0x2pe9qd	28	12	mutations	mutation	NNS
cord-326672-0x2pe9qd	28	13	[	[	-LRB-
cord-326672-0x2pe9qd	28	14	4	4	CD
cord-326672-0x2pe9qd	28	15	,	,	,
cord-326672-0x2pe9qd	28	16	5	5	CD
cord-326672-0x2pe9qd	28	17	]	]	-RRB-
cord-326672-0x2pe9qd	28	18	,	,	,
cord-326672-0x2pe9qd	28	19	and	and	CC
cord-326672-0x2pe9qd	28	20	the	the	DT
cord-326672-0x2pe9qd	28	21	triple	triple	JJ
cord-326672-0x2pe9qd	28	22	combination	combination	NN
cord-326672-0x2pe9qd	28	23	elexacaftor	elexacaftor	NN
cord-326672-0x2pe9qd	28	24	,	,	,
cord-326672-0x2pe9qd	28	25	tezacaftor	tezacaftor	NN
cord-326672-0x2pe9qd	28	26	and	and	CC
cord-326672-0x2pe9qd	28	27	ivacaftor	ivacaftor	NN
cord-326672-0x2pe9qd	28	28	(	(	-LRB-
cord-326672-0x2pe9qd	28	29	Trikafta	Trikafta	NNP
cord-326672-0x2pe9qd	28	30	TM	TM	NNP
cord-326672-0x2pe9qd	28	31	)	)	-RRB-
cord-326672-0x2pe9qd	28	32	in	in	IN
cord-326672-0x2pe9qd	28	33	patients	patient	NNS
cord-326672-0x2pe9qd	28	34	aged	age	VBN
cord-326672-0x2pe9qd	28	35	12	12	CD
cord-326672-0x2pe9qd	28	36	years	year	NNS
cord-326672-0x2pe9qd	28	37	and	and	CC
cord-326672-0x2pe9qd	28	38	older	old	JJR
cord-326672-0x2pe9qd	28	39	who	who	WP
cord-326672-0x2pe9qd	28	40	are	be	VBP
cord-326672-0x2pe9qd	28	41	either	either	DT
cord-326672-0x2pe9qd	28	42	homozygous	homozygous	JJ
cord-326672-0x2pe9qd	28	43	[	[	-LRB-
cord-326672-0x2pe9qd	28	44	6	6	CD
cord-326672-0x2pe9qd	28	45	]	]	-RRB-
cord-326672-0x2pe9qd	28	46	or	or	CC
cord-326672-0x2pe9qd	28	47	heterozygous	heterozygous	JJ
cord-326672-0x2pe9qd	28	48	for	for	IN
cord-326672-0x2pe9qd	28	49	F508del	F508del	NNP
cord-326672-0x2pe9qd	28	50	-	-	HYPH
cord-326672-0x2pe9qd	28	51	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	28	52	[	[	-LRB-
cord-326672-0x2pe9qd	28	53	7	7	CD
cord-326672-0x2pe9qd	28	54	]	]	-RRB-
cord-326672-0x2pe9qd	28	55	.	.	.
cord-326672-0x2pe9qd	29	1	Two	two	CD
cord-326672-0x2pe9qd	29	2	other	other	JJ
cord-326672-0x2pe9qd	29	3	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	29	4	modulator	modulator	NN
cord-326672-0x2pe9qd	29	5	therapies	therapy	NNS
cord-326672-0x2pe9qd	29	6	in	in	IN
cord-326672-0x2pe9qd	29	7	clinical	clinical	JJ
cord-326672-0x2pe9qd	29	8	use	use	NN
cord-326672-0x2pe9qd	29	9	,	,	,
cord-326672-0x2pe9qd	29	10	Orkambi	Orkambi	NNP
cord-326672-0x2pe9qd	29	11	TM	TM	NNP
cord-326672-0x2pe9qd	29	12	,	,	,
cord-326672-0x2pe9qd	29	13	and	and	CC
cord-326672-0x2pe9qd	29	14	Symdeko	Symdeko	NNP
cord-326672-0x2pe9qd	29	15	TM	TM	NNP
cord-326672-0x2pe9qd	29	16	(	(	-LRB-
cord-326672-0x2pe9qd	29	17	also	also	RB
cord-326672-0x2pe9qd	29	18	known	know	VBN
cord-326672-0x2pe9qd	29	19	as	as	IN
cord-326672-0x2pe9qd	29	20	Symkevi	Symkevi	NNP
cord-326672-0x2pe9qd	29	21	TM	TM	NNP
cord-326672-0x2pe9qd	29	22	)	)	-RRB-
cord-326672-0x2pe9qd	29	23	,	,	,
cord-326672-0x2pe9qd	29	24	are	be	VBP
cord-326672-0x2pe9qd	29	25	associated	associate	VBN
cord-326672-0x2pe9qd	29	26	with	with	IN
cord-326672-0x2pe9qd	29	27	more	more	RBR
cord-326672-0x2pe9qd	29	28	modest	modest	JJ
cord-326672-0x2pe9qd	29	29	improvement	improvement	NN
cord-326672-0x2pe9qd	29	30	in	in	IN
cord-326672-0x2pe9qd	29	31	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	29	32	function	function	NN
cord-326672-0x2pe9qd	29	33	and	and	CC
cord-326672-0x2pe9qd	29	34	clinical	clinical	JJ
cord-326672-0x2pe9qd	29	35	outcomes	outcome	NNS
cord-326672-0x2pe9qd	29	36	[	[	-LRB-
cord-326672-0x2pe9qd	29	37	8	8	CD
cord-326672-0x2pe9qd	29	38	,	,	,
cord-326672-0x2pe9qd	29	39	9	9	CD
cord-326672-0x2pe9qd	29	40	]	]	-RRB-
cord-326672-0x2pe9qd	29	41	.	.	.
cord-326672-0x2pe9qd	30	1	Given	give	VBN
cord-326672-0x2pe9qd	30	2	this	this	DT
cord-326672-0x2pe9qd	30	3	background	background	NN
cord-326672-0x2pe9qd	30	4	,	,	,
cord-326672-0x2pe9qd	30	5	and	and	CC
cord-326672-0x2pe9qd	30	6	the	the	DT
cord-326672-0x2pe9qd	30	7	growing	grow	VBG
cord-326672-0x2pe9qd	30	8	common	common	JJ
cord-326672-0x2pe9qd	30	9	usage	usage	NN
cord-326672-0x2pe9qd	30	10	of	of	IN
cord-326672-0x2pe9qd	30	11	this	this	DT
cord-326672-0x2pe9qd	30	12	terminology	terminology	NN
cord-326672-0x2pe9qd	30	13	,	,	,
cord-326672-0x2pe9qd	30	14	why	why	WRB
cord-326672-0x2pe9qd	30	15	should	should	MD
cord-326672-0x2pe9qd	30	16	there	there	EX
cord-326672-0x2pe9qd	30	17	be	be	VB
cord-326672-0x2pe9qd	30	18	any	any	DT
cord-326672-0x2pe9qd	30	19	concern	concern	NN
cord-326672-0x2pe9qd	30	20	about	about	IN
cord-326672-0x2pe9qd	30	21	the	the	DT
cord-326672-0x2pe9qd	30	22	use	use	NN
cord-326672-0x2pe9qd	30	23	of	of	IN
cord-326672-0x2pe9qd	30	24	"	"	``
cord-326672-0x2pe9qd	30	25	highly	highly	RB
cord-326672-0x2pe9qd	30	26	effective	effective	JJ
cord-326672-0x2pe9qd	30	27	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	30	28	modulator	modulator	NN
cord-326672-0x2pe9qd	30	29	"	"	''
cord-326672-0x2pe9qd	30	30	to	to	TO
cord-326672-0x2pe9qd	30	31	differentiate	differentiate	VB
cord-326672-0x2pe9qd	30	32	these	these	DT
cord-326672-0x2pe9qd	30	33	drugs	drug	NNS
cord-326672-0x2pe9qd	30	34	in	in	IN
cord-326672-0x2pe9qd	30	35	the	the	DT
cord-326672-0x2pe9qd	30	36	scientific	scientific	JJ
cord-326672-0x2pe9qd	30	37	literature	literature	NN
cord-326672-0x2pe9qd	30	38	?	?	.
cord-326672-0x2pe9qd	31	1	Drugs	drug	NNS
cord-326672-0x2pe9qd	31	2	are	be	VBP
cord-326672-0x2pe9qd	31	3	classified	classify	VBN
cord-326672-0x2pe9qd	31	4	based	base	VBN
cord-326672-0x2pe9qd	31	5	on	on	IN
cord-326672-0x2pe9qd	31	6	their	-PRON-	PRP$
cord-326672-0x2pe9qd	31	7	pharmacological	pharmacological	JJ
cord-326672-0x2pe9qd	31	8	effects	effect	NNS
cord-326672-0x2pe9qd	31	9	,	,	,
cord-326672-0x2pe9qd	32	1	their	-PRON-	PRP$
cord-326672-0x2pe9qd	32	2	chemical	chemical	NN
cord-326672-0x2pe9qd	32	3	structures	structure	NNS
cord-326672-0x2pe9qd	32	4	,	,	,
cord-326672-0x2pe9qd	32	5	molecular	molecular	JJ
cord-326672-0x2pe9qd	32	6	targets	target	NNS
cord-326672-0x2pe9qd	32	7	or	or	CC
cord-326672-0x2pe9qd	32	8	specific	specific	JJ
cord-326672-0x2pe9qd	32	9	drug	drug	NN
cord-326672-0x2pe9qd	32	10	actions	action	NNS
cord-326672-0x2pe9qd	32	11	,	,	,
cord-326672-0x2pe9qd	32	12	and	and	CC
cord-326672-0x2pe9qd	32	13	the	the	DT
cord-326672-0x2pe9qd	32	14	recognised	recognised	JJ
cord-326672-0x2pe9qd	32	15	classification	classification	NN
cord-326672-0x2pe9qd	32	16	of	of	IN
cord-326672-0x2pe9qd	32	17	"	"	``
cord-326672-0x2pe9qd	32	18	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	32	19	modulators	modulator	NNS
cord-326672-0x2pe9qd	32	20	"	"	''
cord-326672-0x2pe9qd	32	21	fits	fit	VBZ
cord-326672-0x2pe9qd	32	22	nicely	nicely	RB
cord-326672-0x2pe9qd	32	23	within	within	IN
cord-326672-0x2pe9qd	32	24	this	this	DT
cord-326672-0x2pe9qd	32	25	approach	approach	NN
cord-326672-0x2pe9qd	32	26	.	.	.
cord-326672-0x2pe9qd	33	1	As	as	IN
cord-326672-0x2pe9qd	33	2	clinicians	clinician	NNS
cord-326672-0x2pe9qd	33	3	and	and	CC
cord-326672-0x2pe9qd	33	4	scientists	scientist	NNS
cord-326672-0x2pe9qd	33	5	,	,	,
cord-326672-0x2pe9qd	33	6	we	-PRON-	PRP
cord-326672-0x2pe9qd	33	7	describe	describe	VBP
cord-326672-0x2pe9qd	33	8	and	and	CC
cord-326672-0x2pe9qd	33	9	compare	compare	VBP
cord-326672-0x2pe9qd	33	10	specific	specific	JJ
cord-326672-0x2pe9qd	33	11	drugs	drug	NNS
cord-326672-0x2pe9qd	33	12	in	in	IN
cord-326672-0x2pe9qd	33	13	terms	term	NNS
cord-326672-0x2pe9qd	33	14	of	of	IN
cord-326672-0x2pe9qd	33	15	their	-PRON-	PRP$
cord-326672-0x2pe9qd	33	16	potency	potency	NN
cord-326672-0x2pe9qd	33	17	,	,	,
cord-326672-0x2pe9qd	33	18	effect	effect	NN
cord-326672-0x2pe9qd	33	19	or	or	CC
cord-326672-0x2pe9qd	33	20	toxicity	toxicity	NN
cord-326672-0x2pe9qd	33	21	and	and	CC
cord-326672-0x2pe9qd	33	22	such	such	JJ
cord-326672-0x2pe9qd	33	23	comparisons	comparison	NNS
cord-326672-0x2pe9qd	33	24	and	and	CC
cord-326672-0x2pe9qd	33	25	discussion	discussion	NN
cord-326672-0x2pe9qd	33	26	are	be	VBP
cord-326672-0x2pe9qd	33	27	critical	critical	JJ
cord-326672-0x2pe9qd	33	28	in	in	IN
cord-326672-0x2pe9qd	33	29	developing	develop	VBG
cord-326672-0x2pe9qd	33	30	appropriate	appropriate	JJ
cord-326672-0x2pe9qd	33	31	clinical	clinical	JJ
cord-326672-0x2pe9qd	33	32	use	use	NN
cord-326672-0x2pe9qd	33	33	.	.	.
cord-326672-0x2pe9qd	34	1	To	to	IN
cord-326672-0x2pe9qd	34	2	date	date	NN
cord-326672-0x2pe9qd	34	3	,	,	,
cord-326672-0x2pe9qd	34	4	however	however	RB
cord-326672-0x2pe9qd	34	5	the	the	DT
cord-326672-0x2pe9qd	34	6	classification	classification	NN
cord-326672-0x2pe9qd	34	7	of	of	IN
cord-326672-0x2pe9qd	34	8	drugs	drug	NNS
cord-326672-0x2pe9qd	34	9	has	have	VBZ
cord-326672-0x2pe9qd	34	10	not	not	RB
cord-326672-0x2pe9qd	34	11	included	include	VBN
cord-326672-0x2pe9qd	34	12	adjectives	adjective	NNS
cord-326672-0x2pe9qd	34	13	that	that	WDT
cord-326672-0x2pe9qd	34	14	describe	describe	VBP
cord-326672-0x2pe9qd	34	15	them	-PRON-	PRP
cord-326672-0x2pe9qd	34	16	.	.	.
cord-326672-0x2pe9qd	35	1	New	new	JJ
cord-326672-0x2pe9qd	35	2	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	35	3	modulators	modulator	NNS
cord-326672-0x2pe9qd	35	4	are	be	VBP
cord-326672-0x2pe9qd	35	5	in	in	IN
cord-326672-0x2pe9qd	35	6	development	development	NN
cord-326672-0x2pe9qd	35	7	and	and	CC
cord-326672-0x2pe9qd	35	8	,	,	,
cord-326672-0x2pe9qd	35	9	like	like	IN
cord-326672-0x2pe9qd	35	10	other	other	JJ
cord-326672-0x2pe9qd	35	11	new	new	JJ
cord-326672-0x2pe9qd	35	12	drugs	drug	NNS
cord-326672-0x2pe9qd	35	13	,	,	,
cord-326672-0x2pe9qd	35	14	may	may	MD
cord-326672-0x2pe9qd	35	15	end	end	VB
cord-326672-0x2pe9qd	35	16	up	up	RP
cord-326672-0x2pe9qd	35	17	being	be	VBG
cord-326672-0x2pe9qd	35	18	equivalent	equivalent	JJ
cord-326672-0x2pe9qd	35	19	or	or	CC
cord-326672-0x2pe9qd	35	20	may	may	MD
cord-326672-0x2pe9qd	35	21	be	be	VB
cord-326672-0x2pe9qd	35	22	more	more	JJR
cord-326672-0x2pe9qd	35	23	,	,	,
cord-326672-0x2pe9qd	35	24	or	or	CC
cord-326672-0x2pe9qd	35	25	may	may	MD
cord-326672-0x2pe9qd	35	26	be	be	VB
cord-326672-0x2pe9qd	35	27	less	less	RBR
cord-326672-0x2pe9qd	35	28	effective	effective	JJ
cord-326672-0x2pe9qd	35	29	for	for	IN
cord-326672-0x2pe9qd	35	30	specific	specific	JJ
cord-326672-0x2pe9qd	35	31	outcomes	outcome	NNS
cord-326672-0x2pe9qd	35	32	compared	compare	VBN
cord-326672-0x2pe9qd	35	33	with	with	IN
cord-326672-0x2pe9qd	35	34	the	the	DT
cord-326672-0x2pe9qd	35	35	various	various	JJ
cord-326672-0x2pe9qd	35	36	current	current	NN
cord-326672-0x2pe9qd	35	37	clinically	clinically	RB
cord-326672-0x2pe9qd	35	38	available	available	JJ
cord-326672-0x2pe9qd	35	39	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	35	40	modulators	modulator	NNS
cord-326672-0x2pe9qd	35	41	.	.	.
cord-326672-0x2pe9qd	36	1	If	if	IN
cord-326672-0x2pe9qd	36	2	we	-PRON-	PRP
cord-326672-0x2pe9qd	36	3	start	start	VBP
cord-326672-0x2pe9qd	36	4	to	to	TO
cord-326672-0x2pe9qd	36	5	differentiate	differentiate	VB
cord-326672-0x2pe9qd	36	6	within	within	IN
cord-326672-0x2pe9qd	36	7	the	the	DT
cord-326672-0x2pe9qd	36	8	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	36	9	modulator	modulator	NN
cord-326672-0x2pe9qd	36	10	class	class	NN
cord-326672-0x2pe9qd	36	11	in	in	IN
cord-326672-0x2pe9qd	36	12	the	the	DT
cord-326672-0x2pe9qd	36	13	scientific	scientific	JJ
cord-326672-0x2pe9qd	36	14	world	world	NN
cord-326672-0x2pe9qd	36	15	by	by	IN
cord-326672-0x2pe9qd	36	16	the	the	DT
cord-326672-0x2pe9qd	36	17	term	term	NN
cord-326672-0x2pe9qd	36	18	"	"	``
cord-326672-0x2pe9qd	36	19	highly	highly	RB
cord-326672-0x2pe9qd	36	20	effective	effective	JJ
cord-326672-0x2pe9qd	36	21	'	'	''
cord-326672-0x2pe9qd	36	22	,	,	,
cord-326672-0x2pe9qd	36	23	what	what	WP
cord-326672-0x2pe9qd	36	24	will	will	MD
cord-326672-0x2pe9qd	36	25	we	-PRON-	PRP
cord-326672-0x2pe9qd	36	26	use	use	VB
cord-326672-0x2pe9qd	36	27	to	to	TO
cord-326672-0x2pe9qd	36	28	set	set	VB
cord-326672-0x2pe9qd	36	29	the	the	DT
cord-326672-0x2pe9qd	36	30	bar	bar	NN
cord-326672-0x2pe9qd	36	31	to	to	TO
cord-326672-0x2pe9qd	36	32	achieve	achieve	VB
cord-326672-0x2pe9qd	36	33	this	this	DT
cord-326672-0x2pe9qd	36	34	accolade	accolade	NN
cord-326672-0x2pe9qd	36	35	,	,	,
cord-326672-0x2pe9qd	36	36	and	and	CC
cord-326672-0x2pe9qd	36	37	could	could	MD
cord-326672-0x2pe9qd	36	38	there	there	EX
cord-326672-0x2pe9qd	36	39	be	be	VB
cord-326672-0x2pe9qd	36	40	consequences	consequence	NNS
cord-326672-0x2pe9qd	36	41	to	to	IN
cord-326672-0x2pe9qd	36	42	doing	do	VBG
cord-326672-0x2pe9qd	36	43	this	this	DT
cord-326672-0x2pe9qd	36	44	?	?	.
cord-326672-0x2pe9qd	37	1	How	how	WRB
cord-326672-0x2pe9qd	37	2	will	will	MD
cord-326672-0x2pe9qd	37	3	we	-PRON-	PRP
cord-326672-0x2pe9qd	37	4	account	account	VB
cord-326672-0x2pe9qd	37	5	for	for	IN
cord-326672-0x2pe9qd	37	6	variation	variation	NN
cord-326672-0x2pe9qd	37	7	in	in	IN
cord-326672-0x2pe9qd	37	8	effects	effect	NNS
cord-326672-0x2pe9qd	37	9	on	on	IN
cord-326672-0x2pe9qd	37	10	different	different	JJ
cord-326672-0x2pe9qd	37	11	outcomes	outcome	NNS
cord-326672-0x2pe9qd	37	12	or	or	CC
cord-326672-0x2pe9qd	37	13	between	between	IN
cord-326672-0x2pe9qd	37	14	individuals	individual	NNS
cord-326672-0x2pe9qd	37	15	?	?	.
cord-326672-0x2pe9qd	38	1	Naming	name	VBG
cord-326672-0x2pe9qd	38	2	or	or	CC
cord-326672-0x2pe9qd	38	3	labelling	label	VBG
cord-326672-0x2pe9qd	38	4	things	thing	NNS
cord-326672-0x2pe9qd	38	5	is	be	VBZ
cord-326672-0x2pe9qd	38	6	a	a	DT
cord-326672-0x2pe9qd	38	7	very	very	RB
cord-326672-0x2pe9qd	38	8	powerful	powerful	JJ
cord-326672-0x2pe9qd	38	9	tool	tool	NN
cord-326672-0x2pe9qd	38	10	that	that	WDT
cord-326672-0x2pe9qd	38	11	is	be	VBZ
cord-326672-0x2pe9qd	38	12	well	well	RB
cord-326672-0x2pe9qd	38	13	recognised	recognise	VBN
cord-326672-0x2pe9qd	38	14	in	in	IN
cord-326672-0x2pe9qd	38	15	the	the	DT
cord-326672-0x2pe9qd	38	16	advertising	advertising	NN
cord-326672-0x2pe9qd	38	17	world	world	NN
cord-326672-0x2pe9qd	38	18	.	.	.
cord-326672-0x2pe9qd	39	1	In	in	IN
cord-326672-0x2pe9qd	39	2	the	the	DT
cord-326672-0x2pe9qd	39	3	clinical	clinical	JJ
cord-326672-0x2pe9qd	39	4	trial	trial	NN
cord-326672-0x2pe9qd	39	5	setting	set	VBG
cord-326672-0x2pe9qd	39	6	there	there	EX
cord-326672-0x2pe9qd	39	7	has	have	VBZ
cord-326672-0x2pe9qd	39	8	been	be	VBN
cord-326672-0x2pe9qd	39	9	concern	concern	NN
cord-326672-0x2pe9qd	39	10	around	around	IN
cord-326672-0x2pe9qd	39	11	the	the	DT
cord-326672-0x2pe9qd	39	12	explosion	explosion	NN
cord-326672-0x2pe9qd	39	13	in	in	IN
cord-326672-0x2pe9qd	39	14	the	the	DT
cord-326672-0x2pe9qd	39	15	use	use	NN
cord-326672-0x2pe9qd	39	16	of	of	IN
cord-326672-0x2pe9qd	39	17	acronyms	acronym	NNS
cord-326672-0x2pe9qd	39	18	for	for	IN
cord-326672-0x2pe9qd	39	19	naming	name	VBG
cord-326672-0x2pe9qd	39	20	clinical	clinical	JJ
cord-326672-0x2pe9qd	39	21	trials	trial	NNS
cord-326672-0x2pe9qd	39	22	and	and	CC
cord-326672-0x2pe9qd	39	23	the	the	DT
cord-326672-0x2pe9qd	39	24	risks	risk	NNS
cord-326672-0x2pe9qd	39	25	that	that	WDT
cord-326672-0x2pe9qd	39	26	positive	positive	VBP
cord-326672-0x2pe9qd	39	27	sounding	sound	VBG
cord-326672-0x2pe9qd	39	28	trial	trial	NN
cord-326672-0x2pe9qd	39	29	acronyms	acronym	NNS
cord-326672-0x2pe9qd	39	30	pose	pose	VBP
cord-326672-0x2pe9qd	39	31	with	with	IN
cord-326672-0x2pe9qd	39	32	regards	regard	NNS
cord-326672-0x2pe9qd	39	33	to	to	IN
cord-326672-0x2pe9qd	39	34	the	the	DT
cord-326672-0x2pe9qd	39	35	therapeutic	therapeutic	JJ
cord-326672-0x2pe9qd	39	36	misconception	misconception	NN
cord-326672-0x2pe9qd	39	37	[	[	-LRB-
cord-326672-0x2pe9qd	39	38	10	10	CD
cord-326672-0x2pe9qd	39	39	]	]	-RRB-
cord-326672-0x2pe9qd	39	40	.	.	.
cord-326672-0x2pe9qd	40	1	The	the	DT
cord-326672-0x2pe9qd	40	2	language	language	NN
cord-326672-0x2pe9qd	40	3	of	of	IN
cord-326672-0x2pe9qd	40	4	science	science	NN
cord-326672-0x2pe9qd	40	5	should	should	MD
cord-326672-0x2pe9qd	40	6	be	be	VB
cord-326672-0x2pe9qd	40	7	clear	clear	JJ
cord-326672-0x2pe9qd	40	8	and	and	CC
cord-326672-0x2pe9qd	40	9	objective	objective	JJ
cord-326672-0x2pe9qd	40	10	while	while	IN
cord-326672-0x2pe9qd	40	11	still	still	RB
cord-326672-0x2pe9qd	40	12	providing	provide	VBG
cord-326672-0x2pe9qd	40	13	the	the	DT
cord-326672-0x2pe9qd	40	14	opportunity	opportunity	NN
cord-326672-0x2pe9qd	40	15	for	for	IN
cord-326672-0x2pe9qd	40	16	creative	creative	JJ
cord-326672-0x2pe9qd	40	17	thought	thought	NN
cord-326672-0x2pe9qd	40	18	,	,	,
cord-326672-0x2pe9qd	40	19	but	but	CC
cord-326672-0x2pe9qd	40	20	the	the	DT
cord-326672-0x2pe9qd	40	21	labelling	labelling	NN
cord-326672-0x2pe9qd	40	22	of	of	IN
cord-326672-0x2pe9qd	40	23	drugs	drug	NNS
cord-326672-0x2pe9qd	40	24	as	as	IN
cord-326672-0x2pe9qd	40	25	"	"	``
cord-326672-0x2pe9qd	40	26	highly	highly	RB
cord-326672-0x2pe9qd	40	27	effective	effective	JJ
cord-326672-0x2pe9qd	40	28	"	"	''
cord-326672-0x2pe9qd	40	29	as	as	IN
cord-326672-0x2pe9qd	40	30	part	part	NN
cord-326672-0x2pe9qd	40	31	of	of	IN
cord-326672-0x2pe9qd	40	32	their	-PRON-	PRP$
cord-326672-0x2pe9qd	40	33	classification	classification	NN
cord-326672-0x2pe9qd	40	34	feels	feel	VBZ
cord-326672-0x2pe9qd	40	35	close	close	JJ
cord-326672-0x2pe9qd	40	36	to	to	IN
cord-326672-0x2pe9qd	40	37	leaving	leave	VBG
cord-326672-0x2pe9qd	40	38	objectivity	objectivity	NN
cord-326672-0x2pe9qd	40	39	behind	behind	RB
cord-326672-0x2pe9qd	40	40	.	.	.
cord-326672-0x2pe9qd	41	1	The	the	DT
cord-326672-0x2pe9qd	41	2	global	global	JJ
cord-326672-0x2pe9qd	41	3	SARS	SARS	NNP
cord-326672-0x2pe9qd	41	4	-	-	HYPH
cord-326672-0x2pe9qd	41	5	CoV-2	CoV-2	NNP
cord-326672-0x2pe9qd	41	6	pandemic	pandemic	NN
cord-326672-0x2pe9qd	41	7	emerged	emerge	VBD
cord-326672-0x2pe9qd	41	8	after	after	IN
cord-326672-0x2pe9qd	41	9	both	both	DT
cord-326672-0x2pe9qd	41	10	workshops	workshop	NNS
cord-326672-0x2pe9qd	41	11	.	.	.
cord-326672-0x2pe9qd	42	1	The	the	DT
cord-326672-0x2pe9qd	42	2	pandemic	pandemic	NN
cord-326672-0x2pe9qd	42	3	has	have	VBZ
cord-326672-0x2pe9qd	42	4	led	lead	VBN
cord-326672-0x2pe9qd	42	5	to	to	IN
cord-326672-0x2pe9qd	42	6	substantial	substantial	JJ
cord-326672-0x2pe9qd	42	7	impacts	impact	NNS
cord-326672-0x2pe9qd	42	8	on	on	IN
cord-326672-0x2pe9qd	42	9	health	health	NN
cord-326672-0x2pe9qd	42	10	and	and	CC
cord-326672-0x2pe9qd	42	11	on	on	IN
cord-326672-0x2pe9qd	42	12	the	the	DT
cord-326672-0x2pe9qd	42	13	global	global	JJ
cord-326672-0x2pe9qd	42	14	economic	economic	JJ
cord-326672-0x2pe9qd	42	15	outlook	outlook	NN
cord-326672-0x2pe9qd	42	16	.	.	.
cord-326672-0x2pe9qd	43	1	It	-PRON-	PRP
cord-326672-0x2pe9qd	43	2	is	be	VBZ
cord-326672-0x2pe9qd	43	3	likely	likely	JJ
cord-326672-0x2pe9qd	43	4	that	that	IN
cord-326672-0x2pe9qd	43	5	there	there	EX
cord-326672-0x2pe9qd	43	6	will	will	MD
cord-326672-0x2pe9qd	43	7	be	be	VB
cord-326672-0x2pe9qd	43	8	repercussions	repercussion	NNS
cord-326672-0x2pe9qd	43	9	felt	feel	VBN
cord-326672-0x2pe9qd	43	10	across	across	IN
cord-326672-0x2pe9qd	43	11	all	all	DT
cord-326672-0x2pe9qd	43	12	sectors	sector	NNS
cord-326672-0x2pe9qd	43	13	of	of	IN
cord-326672-0x2pe9qd	43	14	the	the	DT
cord-326672-0x2pe9qd	43	15	economy	economy	NN
cord-326672-0x2pe9qd	43	16	,	,	,
cord-326672-0x2pe9qd	43	17	including	include	VBG
cord-326672-0x2pe9qd	43	18	drug	drug	NN
cord-326672-0x2pe9qd	43	19	development	development	NN
cord-326672-0x2pe9qd	43	20	and	and	CC
cord-326672-0x2pe9qd	43	21	support	support	NN
cord-326672-0x2pe9qd	43	22	for	for	IN
cord-326672-0x2pe9qd	43	23	clinical	clinical	JJ
cord-326672-0x2pe9qd	43	24	research	research	NN
cord-326672-0x2pe9qd	43	25	.	.	.
cord-326672-0x2pe9qd	44	1	What	what	WP
cord-326672-0x2pe9qd	44	2	this	this	DT
cord-326672-0x2pe9qd	44	3	means	mean	VBZ
cord-326672-0x2pe9qd	44	4	for	for	IN
cord-326672-0x2pe9qd	44	5	CF	CF	NNP
cord-326672-0x2pe9qd	44	6	research	research	NN
cord-326672-0x2pe9qd	44	7	and	and	CC
cord-326672-0x2pe9qd	44	8	the	the	DT
cord-326672-0x2pe9qd	44	9	pipeline	pipeline	NN
cord-326672-0x2pe9qd	44	10	of	of	IN
cord-326672-0x2pe9qd	44	11	new	new	JJ
cord-326672-0x2pe9qd	44	12	treatments	treatment	NNS
cord-326672-0x2pe9qd	44	13	for	for	IN
cord-326672-0x2pe9qd	44	14	CF	CF	NNP
cord-326672-0x2pe9qd	44	15	specifically	specifically	RB
cord-326672-0x2pe9qd	44	16	,	,	,
cord-326672-0x2pe9qd	44	17	or	or	CC
cord-326672-0x2pe9qd	44	18	indeed	indeed	RB
cord-326672-0x2pe9qd	44	19	for	for	IN
cord-326672-0x2pe9qd	44	20	how	how	WRB
cord-326672-0x2pe9qd	44	21	clinical	clinical	JJ
cord-326672-0x2pe9qd	44	22	trials	trial	NNS
cord-326672-0x2pe9qd	44	23	will	will	MD
cord-326672-0x2pe9qd	44	24	be	be	VB
cord-326672-0x2pe9qd	44	25	conducted	conduct	VBN
cord-326672-0x2pe9qd	44	26	,	,	,
cord-326672-0x2pe9qd	44	27	or	or	CC
cord-326672-0x2pe9qd	44	28	new	new	JJ
cord-326672-0x2pe9qd	44	29	therapies	therapy	NNS
cord-326672-0x2pe9qd	44	30	may	may	MD
cord-326672-0x2pe9qd	44	31	be	be	VB
cord-326672-0x2pe9qd	44	32	reimbursed	reimburse	VBN
cord-326672-0x2pe9qd	44	33	in	in	IN
cord-326672-0x2pe9qd	44	34	the	the	DT
cord-326672-0x2pe9qd	44	35	future	future	NN
cord-326672-0x2pe9qd	44	36	,	,	,
cord-326672-0x2pe9qd	44	37	remains	remain	VBZ
cord-326672-0x2pe9qd	44	38	to	to	TO
cord-326672-0x2pe9qd	44	39	be	be	VB
cord-326672-0x2pe9qd	44	40	seen	see	VBN
cord-326672-0x2pe9qd	44	41	.	.	.
cord-326672-0x2pe9qd	45	1	The	the	DT
cord-326672-0x2pe9qd	45	2	pandemic	pandemic	NN
cord-326672-0x2pe9qd	45	3	however	however	RB
cord-326672-0x2pe9qd	45	4	has	have	VBZ
cord-326672-0x2pe9qd	45	5	prompted	prompt	VBN
cord-326672-0x2pe9qd	45	6	urgent	urgent	JJ
cord-326672-0x2pe9qd	45	7	collaboration	collaboration	NN
cord-326672-0x2pe9qd	45	8	globally	globally	RB
cord-326672-0x2pe9qd	45	9	to	to	TO
cord-326672-0x2pe9qd	45	10	develop	develop	VB
cord-326672-0x2pe9qd	45	11	vaccination	vaccination	NN
cord-326672-0x2pe9qd	45	12	and	and	CC
cord-326672-0x2pe9qd	45	13	treatments	treatment	NNS
cord-326672-0x2pe9qd	45	14	to	to	TO
cord-326672-0x2pe9qd	45	15	combat	combat	VB
cord-326672-0x2pe9qd	45	16	COVID-19	COVID-19	NNP
cord-326672-0x2pe9qd	45	17	,	,	,
cord-326672-0x2pe9qd	45	18	the	the	DT
cord-326672-0x2pe9qd	45	19	disease	disease	NN
cord-326672-0x2pe9qd	45	20	caused	cause	VBN
cord-326672-0x2pe9qd	45	21	by	by	IN
cord-326672-0x2pe9qd	45	22	SARS	SARS	NNP
cord-326672-0x2pe9qd	45	23	-	-	HYPH
cord-326672-0x2pe9qd	45	24	CoV-2	CoV-2	NNP
cord-326672-0x2pe9qd	45	25	.	.	.
cord-326672-0x2pe9qd	46	1	In	in	IN
cord-326672-0x2pe9qd	46	2	June	June	NNP
cord-326672-0x2pe9qd	46	3	2020	2020	CD
cord-326672-0x2pe9qd	46	4	,	,	,
cord-326672-0x2pe9qd	46	5	a	a	DT
cord-326672-0x2pe9qd	46	6	great	great	JJ
cord-326672-0x2pe9qd	46	7	start	start	NN
cord-326672-0x2pe9qd	46	8	was	be	VBD
cord-326672-0x2pe9qd	46	9	made	make	VBN
cord-326672-0x2pe9qd	46	10	in	in	IN
cord-326672-0x2pe9qd	46	11	regulatory	regulatory	JJ
cord-326672-0x2pe9qd	46	12	harmonization	harmonization	NN
cord-326672-0x2pe9qd	46	13	with	with	IN
cord-326672-0x2pe9qd	46	14	a	a	DT
cord-326672-0x2pe9qd	46	15	meeting	meeting	NN
cord-326672-0x2pe9qd	46	16	chaired	chair	VBN
cord-326672-0x2pe9qd	46	17	by	by	IN
cord-326672-0x2pe9qd	46	18	the	the	DT
cord-326672-0x2pe9qd	46	19	FDA	FDA	NNP
cord-326672-0x2pe9qd	46	20	and	and	CC
cord-326672-0x2pe9qd	46	21	EMA	EMA	NNP
cord-326672-0x2pe9qd	46	22	under	under	IN
cord-326672-0x2pe9qd	46	23	the	the	DT
cord-326672-0x2pe9qd	46	24	auspices	auspex	NNS
cord-326672-0x2pe9qd	46	25	of	of	IN
cord-326672-0x2pe9qd	46	26	the	the	DT
cord-326672-0x2pe9qd	46	27	International	International	NNP
cord-326672-0x2pe9qd	46	28	Coalition	Coalition	NNP
cord-326672-0x2pe9qd	46	29	of	of	IN
cord-326672-0x2pe9qd	46	30	Medicines	Medicines	NNP
cord-326672-0x2pe9qd	46	31	Regulatory	Regulatory	NNP
cord-326672-0x2pe9qd	46	32	Agencies	Agencies	NNPS
cord-326672-0x2pe9qd	47	1	(	(	-LRB-
cord-326672-0x2pe9qd	47	2	ICMRA	ICMRA	NNP
cord-326672-0x2pe9qd	47	3	,	,	,
cord-326672-0x2pe9qd	47	4	)	)	-RRB-
cord-326672-0x2pe9qd	47	5	which	which	WDT
cord-326672-0x2pe9qd	47	6	brought	bring	VBD
cord-326672-0x2pe9qd	47	7	together	together	RB
cord-326672-0x2pe9qd	47	8	experts	expert	NNS
cord-326672-0x2pe9qd	47	9	from	from	IN
cord-326672-0x2pe9qd	47	10	over	over	IN
cord-326672-0x2pe9qd	47	11	20	20	CD
cord-326672-0x2pe9qd	47	12	countries	country	NNS
cord-326672-0x2pe9qd	47	13	and	and	CC
cord-326672-0x2pe9qd	47	14	28	28	CD
cord-326672-0x2pe9qd	47	15	regulatory	regulatory	JJ
cord-326672-0x2pe9qd	47	16	authorities	authority	NNS
cord-326672-0x2pe9qd	47	17	.	.	.
cord-326672-0x2pe9qd	48	1	The	the	DT
cord-326672-0x2pe9qd	48	2	meeting	meeting	NN
cord-326672-0x2pe9qd	48	3	led	lead	VBD
cord-326672-0x2pe9qd	48	4	to	to	IN
cord-326672-0x2pe9qd	48	5	broad	broad	JJ
cord-326672-0x2pe9qd	48	6	agreement	agreement	NN
cord-326672-0x2pe9qd	48	7	on	on	IN
cord-326672-0x2pe9qd	48	8	the	the	DT
cord-326672-0x2pe9qd	48	9	data	datum	NNS
cord-326672-0x2pe9qd	48	10	required	require	VBN
cord-326672-0x2pe9qd	48	11	from	from	IN
cord-326672-0x2pe9qd	48	12	laboratory	laboratory	NN
cord-326672-0x2pe9qd	48	13	,	,	,
cord-326672-0x2pe9qd	48	14	animal	animal	NN
cord-326672-0x2pe9qd	48	15	and	and	CC
cord-326672-0x2pe9qd	48	16	human	human	JJ
cord-326672-0x2pe9qd	48	17	research	research	NN
cord-326672-0x2pe9qd	48	18	as	as	RB
cord-326672-0x2pe9qd	48	19	well	well	RB
cord-326672-0x2pe9qd	48	20	as	as	IN
cord-326672-0x2pe9qd	48	21	aspects	aspect	NNS
cord-326672-0x2pe9qd	48	22	of	of	IN
cord-326672-0x2pe9qd	48	23	Phase	phase	NN
cord-326672-0x2pe9qd	48	24	3	3	CD
cord-326672-0x2pe9qd	48	25	clinical	clinical	JJ
cord-326672-0x2pe9qd	48	26	trials	trial	NNS
cord-326672-0x2pe9qd	48	27	aimed	aim	VBN
cord-326672-0x2pe9qd	48	28	at	at	IN
cord-326672-0x2pe9qd	48	29	the	the	DT
cord-326672-0x2pe9qd	48	30	rapid	rapid	JJ
cord-326672-0x2pe9qd	48	31	development	development	NN
cord-326672-0x2pe9qd	48	32	and	and	CC
cord-326672-0x2pe9qd	48	33	regulatory	regulatory	JJ
cord-326672-0x2pe9qd	48	34	approval	approval	NN
cord-326672-0x2pe9qd	48	35	for	for	IN
cord-326672-0x2pe9qd	48	36	vaccines	vaccine	NNS
cord-326672-0x2pe9qd	48	37	for	for	IN
cord-326672-0x2pe9qd	48	38	COVID-19	covid-19	NN
cord-326672-0x2pe9qd	48	39	.	.	.
cord-326672-0x2pe9qd	49	1	We	-PRON-	PRP
cord-326672-0x2pe9qd	49	2	can	can	MD
cord-326672-0x2pe9qd	49	3	only	only	RB
cord-326672-0x2pe9qd	49	4	hope	hope	VB
cord-326672-0x2pe9qd	49	5	that	that	IN
cord-326672-0x2pe9qd	49	6	this	this	DT
cord-326672-0x2pe9qd	49	7	example	example	NN
cord-326672-0x2pe9qd	49	8	of	of	IN
cord-326672-0x2pe9qd	49	9	global	global	JJ
cord-326672-0x2pe9qd	49	10	collaboration	collaboration	NN
cord-326672-0x2pe9qd	49	11	will	will	MD
cord-326672-0x2pe9qd	49	12	lead	lead	VB
cord-326672-0x2pe9qd	49	13	to	to	IN
cord-326672-0x2pe9qd	49	14	a	a	DT
cord-326672-0x2pe9qd	49	15	more	more	RBR
cord-326672-0x2pe9qd	49	16	established	established	JJ
cord-326672-0x2pe9qd	49	17	pattern	pattern	NN
cord-326672-0x2pe9qd	49	18	of	of	IN
cord-326672-0x2pe9qd	49	19	harmonization	harmonization	NN
cord-326672-0x2pe9qd	49	20	and	and	CC
cord-326672-0x2pe9qd	49	21	more	more	RBR
cord-326672-0x2pe9qd	49	22	rapid	rapid	JJ
cord-326672-0x2pe9qd	49	23	development	development	NN
cord-326672-0x2pe9qd	49	24	of	of	IN
cord-326672-0x2pe9qd	49	25	other	other	JJ
cord-326672-0x2pe9qd	49	26	important	important	JJ
cord-326672-0x2pe9qd	49	27	medicines	medicine	NNS
cord-326672-0x2pe9qd	49	28	in	in	IN
cord-326672-0x2pe9qd	49	29	the	the	DT
cord-326672-0x2pe9qd	49	30	future	future	NN
cord-326672-0x2pe9qd	49	31	.	.	.
cord-326672-0x2pe9qd	50	1	The	the	DT
cord-326672-0x2pe9qd	50	2	outputs	output	NNS
cord-326672-0x2pe9qd	50	3	from	from	IN
cord-326672-0x2pe9qd	50	4	the	the	DT
cord-326672-0x2pe9qd	50	5	two	two	CD
cord-326672-0x2pe9qd	50	6	workshops	workshop	NNS
cord-326672-0x2pe9qd	50	7	have	have	VBP
cord-326672-0x2pe9qd	50	8	provided	provide	VBN
cord-326672-0x2pe9qd	50	9	a	a	DT
cord-326672-0x2pe9qd	50	10	very	very	RB
cord-326672-0x2pe9qd	50	11	helpful	helpful	JJ
cord-326672-0x2pe9qd	50	12	start	start	NN
cord-326672-0x2pe9qd	50	13	in	in	IN
cord-326672-0x2pe9qd	50	14	setting	set	VBG
cord-326672-0x2pe9qd	50	15	the	the	DT
cord-326672-0x2pe9qd	50	16	scene	scene	NN
cord-326672-0x2pe9qd	50	17	for	for	IN
cord-326672-0x2pe9qd	50	18	clinical	clinical	JJ
cord-326672-0x2pe9qd	50	19	development	development	NN
cord-326672-0x2pe9qd	50	20	of	of	IN
cord-326672-0x2pe9qd	50	21	new	new	JJ
cord-326672-0x2pe9qd	50	22	treatments	treatment	NNS
cord-326672-0x2pe9qd	50	23	for	for	IN
cord-326672-0x2pe9qd	50	24	CF	cf	NN
cord-326672-0x2pe9qd	50	25	in	in	IN
cord-326672-0x2pe9qd	50	26	the	the	DT
cord-326672-0x2pe9qd	50	27	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	50	28	modulator	modulator	NN
cord-326672-0x2pe9qd	50	29	era	era	NN
cord-326672-0x2pe9qd	50	30	.	.	.
cord-326672-0x2pe9qd	51	1	There	there	EX
cord-326672-0x2pe9qd	51	2	were	be	VBD
cord-326672-0x2pe9qd	51	3	some	some	DT
cord-326672-0x2pe9qd	51	4	issues	issue	NNS
cord-326672-0x2pe9qd	51	5	however	however	RB
cord-326672-0x2pe9qd	51	6	that	that	WDT
cord-326672-0x2pe9qd	51	7	may	may	MD
cord-326672-0x2pe9qd	51	8	benefit	benefit	VB
cord-326672-0x2pe9qd	51	9	from	from	IN
cord-326672-0x2pe9qd	51	10	further	further	JJ
cord-326672-0x2pe9qd	51	11	consideration	consideration	NN
cord-326672-0x2pe9qd	51	12	in	in	IN
cord-326672-0x2pe9qd	51	13	the	the	DT
cord-326672-0x2pe9qd	51	14	future	future	NN
cord-326672-0x2pe9qd	51	15	.	.	.
cord-326672-0x2pe9qd	52	1	The	the	DT
cord-326672-0x2pe9qd	52	2	high	high	JJ
cord-326672-0x2pe9qd	52	3	cost	cost	NN
cord-326672-0x2pe9qd	52	4	of	of	IN
cord-326672-0x2pe9qd	52	5	new	new	JJ
cord-326672-0x2pe9qd	52	6	treatments	treatment	NNS
cord-326672-0x2pe9qd	52	7	and	and	CC
cord-326672-0x2pe9qd	52	8	reimbursement	reimbursement	NN
cord-326672-0x2pe9qd	52	9	remains	remain	VBZ
cord-326672-0x2pe9qd	52	10	a	a	DT
cord-326672-0x2pe9qd	52	11	considerable	considerable	JJ
cord-326672-0x2pe9qd	52	12	concern	concern	NN
cord-326672-0x2pe9qd	52	13	for	for	IN
cord-326672-0x2pe9qd	52	14	CF	CF	NNP
cord-326672-0x2pe9qd	52	15	care	care	NN
cord-326672-0x2pe9qd	52	16	.	.	.
cord-326672-0x2pe9qd	53	1	This	this	DT
cord-326672-0x2pe9qd	53	2	of	of	IN
cord-326672-0x2pe9qd	53	3	course	course	NN
cord-326672-0x2pe9qd	53	4	is	be	VBZ
cord-326672-0x2pe9qd	53	5	a	a	DT
cord-326672-0x2pe9qd	53	6	thorny	thorny	JJ
cord-326672-0x2pe9qd	53	7	global	global	JJ
cord-326672-0x2pe9qd	53	8	issue	issue	NN
cord-326672-0x2pe9qd	53	9	for	for	IN
cord-326672-0x2pe9qd	53	10	all	all	DT
cord-326672-0x2pe9qd	53	11	areas	area	NNS
cord-326672-0x2pe9qd	53	12	of	of	IN
cord-326672-0x2pe9qd	53	13	health	health	NN
cord-326672-0x2pe9qd	53	14	worldwide	worldwide	RB
cord-326672-0x2pe9qd	53	15	,	,	,
cord-326672-0x2pe9qd	53	16	and	and	CC
cord-326672-0x2pe9qd	53	17	while	while	IN
cord-326672-0x2pe9qd	53	18	there	there	EX
cord-326672-0x2pe9qd	53	19	are	be	VBP
cord-326672-0x2pe9qd	53	20	no	no	DT
cord-326672-0x2pe9qd	53	21	easy	easy	JJ
cord-326672-0x2pe9qd	53	22	solutions	solution	NNS
cord-326672-0x2pe9qd	53	23	,	,	,
cord-326672-0x2pe9qd	53	24	we	-PRON-	PRP
cord-326672-0x2pe9qd	53	25	need	need	VBP
cord-326672-0x2pe9qd	53	26	to	to	TO
cord-326672-0x2pe9qd	53	27	keep	keep	VB
cord-326672-0x2pe9qd	53	28	reconsidering	reconsider	VBG
cord-326672-0x2pe9qd	53	29	the	the	DT
cord-326672-0x2pe9qd	53	30	issues	issue	NNS
cord-326672-0x2pe9qd	53	31	and	and	CC
cord-326672-0x2pe9qd	53	32	chip	chip	VB
cord-326672-0x2pe9qd	53	33	away	away	RB
cord-326672-0x2pe9qd	53	34	at	at	IN
cord-326672-0x2pe9qd	53	35	the	the	DT
cord-326672-0x2pe9qd	53	36	problem	problem	NN
cord-326672-0x2pe9qd	53	37	.	.	.
cord-326672-0x2pe9qd	54	1	The	the	DT
cord-326672-0x2pe9qd	54	2	other	other	JJ
cord-326672-0x2pe9qd	54	3	major	major	JJ
cord-326672-0x2pe9qd	54	4	area	area	NN
cord-326672-0x2pe9qd	54	5	that	that	WDT
cord-326672-0x2pe9qd	54	6	deserves	deserve	VBZ
cord-326672-0x2pe9qd	54	7	further	further	RB
cord-326672-0x2pe9qd	54	8	thought	thought	NN
cord-326672-0x2pe9qd	54	9	includes	include	VBZ
cord-326672-0x2pe9qd	54	10	trials	trial	NNS
cord-326672-0x2pe9qd	54	11	and	and	CC
cord-326672-0x2pe9qd	54	12	regulatory	regulatory	JJ
cord-326672-0x2pe9qd	54	13	pathways	pathway	NNS
cord-326672-0x2pe9qd	54	14	for	for	IN
cord-326672-0x2pe9qd	54	15	new	new	JJ
cord-326672-0x2pe9qd	54	16	medicines	medicine	NNS
cord-326672-0x2pe9qd	54	17	in	in	IN
cord-326672-0x2pe9qd	54	18	vulnerable	vulnerable	JJ
cord-326672-0x2pe9qd	54	19	groups	group	NNS
cord-326672-0x2pe9qd	54	20	such	such	JJ
cord-326672-0x2pe9qd	54	21	as	as	IN
cord-326672-0x2pe9qd	54	22	pregnant	pregnant	JJ
cord-326672-0x2pe9qd	54	23	or	or	CC
cord-326672-0x2pe9qd	54	24	lactating	lactate	VBG
cord-326672-0x2pe9qd	54	25	mothers	mother	NNS
cord-326672-0x2pe9qd	54	26	,	,	,
cord-326672-0x2pe9qd	54	27	those	those	DT
cord-326672-0x2pe9qd	54	28	with	with	IN
cord-326672-0x2pe9qd	54	29	solid	solid	JJ
cord-326672-0x2pe9qd	54	30	organ	organ	NN
cord-326672-0x2pe9qd	54	31	transplants	transplant	NNS
cord-326672-0x2pe9qd	54	32	,	,	,
cord-326672-0x2pe9qd	54	33	and	and	CC
cord-326672-0x2pe9qd	54	34	those	those	DT
cord-326672-0x2pe9qd	54	35	with	with	IN
cord-326672-0x2pe9qd	54	36	severe	severe	JJ
cord-326672-0x2pe9qd	54	37	liver	liver	NN
cord-326672-0x2pe9qd	54	38	disease	disease	NN
cord-326672-0x2pe9qd	54	39	.	.	.
cord-326672-0x2pe9qd	55	1	These	these	DT
cord-326672-0x2pe9qd	55	2	groups	group	NNS
cord-326672-0x2pe9qd	55	3	are	be	VBP
cord-326672-0x2pe9qd	55	4	almost	almost	RB
cord-326672-0x2pe9qd	55	5	always	always	RB
cord-326672-0x2pe9qd	55	6	excluded	exclude	VBN
cord-326672-0x2pe9qd	55	7	from	from	IN
cord-326672-0x2pe9qd	55	8	clinical	clinical	JJ
cord-326672-0x2pe9qd	55	9	trials	trial	NNS
cord-326672-0x2pe9qd	55	10	and	and	CC
cord-326672-0x2pe9qd	55	11	regulatory	regulatory	JJ
cord-326672-0x2pe9qd	55	12	packages	package	NNS
cord-326672-0x2pe9qd	55	13	although	although	IN
cord-326672-0x2pe9qd	55	14	clinicians	clinician	NNS
cord-326672-0x2pe9qd	55	15	and	and	CC
cord-326672-0x2pe9qd	55	16	patients	patient	NNS
cord-326672-0x2pe9qd	55	17	may	may	MD
cord-326672-0x2pe9qd	55	18	choose	choose	VB
cord-326672-0x2pe9qd	55	19	to	to	TO
cord-326672-0x2pe9qd	55	20	use	use	VB
cord-326672-0x2pe9qd	55	21	the	the	DT
cord-326672-0x2pe9qd	55	22	medicines	medicine	NNS
cord-326672-0x2pe9qd	55	23	once	once	IN
cord-326672-0x2pe9qd	55	24	they	-PRON-	PRP
cord-326672-0x2pe9qd	55	25	are	be	VBP
cord-326672-0x2pe9qd	55	26	generally	generally	RB
cord-326672-0x2pe9qd	55	27	approved	approve	VBN
cord-326672-0x2pe9qd	55	28	.	.	.
cord-326672-0x2pe9qd	56	1	There	there	EX
cord-326672-0x2pe9qd	56	2	has	have	VBZ
cord-326672-0x2pe9qd	56	3	been	be	VBN
cord-326672-0x2pe9qd	56	4	some	some	DT
cord-326672-0x2pe9qd	56	5	encouraging	encouraging	JJ
cord-326672-0x2pe9qd	56	6	progress	progress	NN
cord-326672-0x2pe9qd	56	7	recently	recently	RB
cord-326672-0x2pe9qd	56	8	with	with	IN
cord-326672-0x2pe9qd	56	9	the	the	DT
cord-326672-0x2pe9qd	56	10	2018	2018	CD
cord-326672-0x2pe9qd	56	11	FDA	FDA	NNP
cord-326672-0x2pe9qd	56	12	guidance	guidance	NN
cord-326672-0x2pe9qd	56	13	on	on	IN
cord-326672-0x2pe9qd	56	14	the	the	DT
cord-326672-0x2pe9qd	56	15	issue	issue	NN
cord-326672-0x2pe9qd	56	16	of	of	IN
cord-326672-0x2pe9qd	56	17	trialling	trialle	VBG
cord-326672-0x2pe9qd	56	18	and	and	CC
cord-326672-0x2pe9qd	56	19	monitoring	monitor	VBG
cord-326672-0x2pe9qd	56	20	medicines	medicine	NNS
cord-326672-0x2pe9qd	56	21	during	during	IN
cord-326672-0x2pe9qd	56	22	pregnancy	pregnancy	NN
cord-326672-0x2pe9qd	56	23	and	and	CC
cord-326672-0x2pe9qd	56	24	lactation	lactation	NN
cord-326672-0x2pe9qd	56	25	.	.	.
cord-326672-0x2pe9qd	57	1	Future	future	JJ
cord-326672-0x2pe9qd	57	2	collaboration	collaboration	NN
cord-326672-0x2pe9qd	57	3	and	and	CC
cord-326672-0x2pe9qd	57	4	communication	communication	NN
cord-326672-0x2pe9qd	57	5	between	between	IN
cord-326672-0x2pe9qd	57	6	regulatory	regulatory	JJ
cord-326672-0x2pe9qd	57	7	authorities	authority	NNS
cord-326672-0x2pe9qd	57	8	,	,	,
cord-326672-0x2pe9qd	57	9	pharmaceutical	pharmaceutical	NN
cord-326672-0x2pe9qd	57	10	companies	company	NNS
cord-326672-0x2pe9qd	57	11	,	,	,
cord-326672-0x2pe9qd	57	12	clinicians	clinician	NNS
cord-326672-0x2pe9qd	57	13	and	and	CC
cord-326672-0x2pe9qd	57	14	patient	patient	JJ
cord-326672-0x2pe9qd	57	15	groups	group	NNS
cord-326672-0x2pe9qd	57	16	will	will	MD
cord-326672-0x2pe9qd	57	17	be	be	VB
cord-326672-0x2pe9qd	57	18	needed	need	VBN
cord-326672-0x2pe9qd	57	19	to	to	TO
cord-326672-0x2pe9qd	57	20	consider	consider	VB
cord-326672-0x2pe9qd	57	21	how	how	WRB
cord-326672-0x2pe9qd	57	22	best	good	JJS
cord-326672-0x2pe9qd	57	23	to	to	TO
cord-326672-0x2pe9qd	57	24	establish	establish	VB
cord-326672-0x2pe9qd	57	25	the	the	DT
cord-326672-0x2pe9qd	57	26	clinical	clinical	JJ
cord-326672-0x2pe9qd	57	27	use	use	NN
cord-326672-0x2pe9qd	57	28	of	of	IN
cord-326672-0x2pe9qd	57	29	new	new	JJ
cord-326672-0x2pe9qd	57	30	CF	CF	NNP
cord-326672-0x2pe9qd	57	31	medicines	medicine	NNS
cord-326672-0x2pe9qd	57	32	for	for	IN
cord-326672-0x2pe9qd	57	33	these	these	DT
cord-326672-0x2pe9qd	57	34	very	very	RB
cord-326672-0x2pe9qd	57	35	challenging	challenging	JJ
cord-326672-0x2pe9qd	57	36	populations	population	NNS
cord-326672-0x2pe9qd	57	37	.	.	.
cord-326672-0x2pe9qd	58	1	There	there	EX
cord-326672-0x2pe9qd	58	2	has	have	VBZ
cord-326672-0x2pe9qd	58	3	been	be	VBN
cord-326672-0x2pe9qd	58	4	enormous	enormous	JJ
cord-326672-0x2pe9qd	58	5	improvement	improvement	NN
cord-326672-0x2pe9qd	58	6	and	and	CC
cord-326672-0x2pe9qd	58	7	exciting	exciting	JJ
cord-326672-0x2pe9qd	58	8	development	development	NN
cord-326672-0x2pe9qd	58	9	in	in	IN
cord-326672-0x2pe9qd	58	10	CF	CF	NNP
cord-326672-0x2pe9qd	58	11	care	care	NN
cord-326672-0x2pe9qd	58	12	especially	especially	RB
cord-326672-0x2pe9qd	58	13	with	with	IN
cord-326672-0x2pe9qd	58	14	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	58	15	modulation	modulation	NN
cord-326672-0x2pe9qd	58	16	,	,	,
cord-326672-0x2pe9qd	58	17	but	but	CC
cord-326672-0x2pe9qd	58	18	much	much	JJ
cord-326672-0x2pe9qd	58	19	work	work	NN
cord-326672-0x2pe9qd	58	20	remains	remain	VBZ
cord-326672-0x2pe9qd	58	21	to	to	TO
cord-326672-0x2pe9qd	58	22	be	be	VB
cord-326672-0x2pe9qd	58	23	done	do	VBN
cord-326672-0x2pe9qd	58	24	to	to	TO
cord-326672-0x2pe9qd	58	25	ensure	ensure	VB
cord-326672-0x2pe9qd	58	26	equi-	equi-	JJ
cord-326672-0x2pe9qd	58	27	 	 	_SP
cord-326672-0x2pe9qd	59	1	Cystic	cystic	JJ
cord-326672-0x2pe9qd	59	2	fibrosis	fibrosis	NN
cord-326672-0x2pe9qd	59	3	drug	drug	NN
cord-326672-0x2pe9qd	59	4	trial	trial	NN
cord-326672-0x2pe9qd	59	5	design	design	NN
cord-326672-0x2pe9qd	59	6	in	in	IN
cord-326672-0x2pe9qd	59	7	the	the	DT
cord-326672-0x2pe9qd	59	8	era	era	NN
cord-326672-0x2pe9qd	59	9	of	of	IN
cord-326672-0x2pe9qd	59	10	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	59	11	modulators	modulator	NNS
cord-326672-0x2pe9qd	59	12	associated	associate	VBN
cord-326672-0x2pe9qd	59	13	with	with	IN
cord-326672-0x2pe9qd	59	14	substantial	substantial	JJ
cord-326672-0x2pe9qd	59	15	clinical	clinical	JJ
cord-326672-0x2pe9qd	59	16	benefit	benefit	NN
cord-326672-0x2pe9qd	59	17	:	:	:
cord-326672-0x2pe9qd	59	18	stakeholders	stakeholder	NNS
cord-326672-0x2pe9qd	59	19	consensus	consensus	NN
cord-326672-0x2pe9qd	59	20	view	view	NN
cord-326672-0x2pe9qd	60	1	Building	build	VBG
cord-326672-0x2pe9qd	60	2	global	global	JJ
cord-326672-0x2pe9qd	60	3	development	development	NN
cord-326672-0x2pe9qd	60	4	strategies	strategy	NNS
cord-326672-0x2pe9qd	60	5	for	for	IN
cord-326672-0x2pe9qd	60	6	CF	CF	NNP
cord-326672-0x2pe9qd	60	7	therapeutics	therapeutic	NNS
cord-326672-0x2pe9qd	60	8	during	during	IN
cord-326672-0x2pe9qd	60	9	a	a	DT
cord-326672-0x2pe9qd	60	10	transitional	transitional	JJ
cord-326672-0x2pe9qd	60	11	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	60	12	modulator	modulator	NN
cord-326672-0x2pe9qd	60	13	era	era	NN
cord-326672-0x2pe9qd	61	1	The	the	DT
cord-326672-0x2pe9qd	61	2	U.S.	U.S.	NNP
cord-326672-0x2pe9qd	61	3	food	food	NN
cord-326672-0x2pe9qd	61	4	and	and	CC
cord-326672-0x2pe9qd	61	5	drug	drug	NNP
cord-326672-0x2pe9qd	61	6	administration	administration	NNP
cord-326672-0x2pe9qd	61	7	's	's	POS
cord-326672-0x2pe9qd	61	8	experience	experience	NN
cord-326672-0x2pe9qd	61	9	with	with	IN
cord-326672-0x2pe9qd	61	10	ivacaftor	ivacaftor	NN
cord-326672-0x2pe9qd	61	11	in	in	IN
cord-326672-0x2pe9qd	61	12	cystic	cystic	JJ
cord-326672-0x2pe9qd	61	13	fibrosis	fibrosis	NN
cord-326672-0x2pe9qd	61	14	.	.	.
cord-326672-0x2pe9qd	62	1	establishing	establish	VBG
cord-326672-0x2pe9qd	62	2	efficacy	efficacy	NN
cord-326672-0x2pe9qd	62	3	using	use	VBG
cord-326672-0x2pe9qd	62	4	in	in	IN
cord-326672-0x2pe9qd	62	5	vitro	vitro	FW
cord-326672-0x2pe9qd	62	6	data	datum	NNS
cord-326672-0x2pe9qd	62	7	in	in	IN
cord-326672-0x2pe9qd	62	8	lieu	lieu	NN
cord-326672-0x2pe9qd	62	9	of	of	IN
cord-326672-0x2pe9qd	62	10	a	a	DT
cord-326672-0x2pe9qd	62	11	clinical	clinical	JJ
cord-326672-0x2pe9qd	62	12	trial	trial	NN
cord-326672-0x2pe9qd	62	13	A	a	DT
cord-326672-0x2pe9qd	62	14	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	62	15	potentiator	potentiator	NN
cord-326672-0x2pe9qd	62	16	in	in	IN
cord-326672-0x2pe9qd	62	17	patients	patient	NNS
cord-326672-0x2pe9qd	62	18	with	with	IN
cord-326672-0x2pe9qd	62	19	cystic	cystic	JJ
cord-326672-0x2pe9qd	62	20	fibrosis	fibrosis	NN
cord-326672-0x2pe9qd	62	21	and	and	CC
cord-326672-0x2pe9qd	62	22	the	the	DT
cord-326672-0x2pe9qd	62	23	G551D	G551D	NNP
cord-326672-0x2pe9qd	62	24	mutation	mutation	NN
cord-326672-0x2pe9qd	62	25	Efficacy	Efficacy	NNP
cord-326672-0x2pe9qd	62	26	and	and	CC
cord-326672-0x2pe9qd	62	27	safety	safety	NN
cord-326672-0x2pe9qd	62	28	of	of	IN
cord-326672-0x2pe9qd	62	29	ivacaftor	ivacaftor	NN
cord-326672-0x2pe9qd	62	30	in	in	IN
cord-326672-0x2pe9qd	62	31	patients	patient	NNS
cord-326672-0x2pe9qd	62	32	aged	age	VBN
cord-326672-0x2pe9qd	62	33	6	6	CD
cord-326672-0x2pe9qd	62	34	-	-	SYM
cord-326672-0x2pe9qd	62	35	11	11	CD
cord-326672-0x2pe9qd	62	36	years	year	NNS
cord-326672-0x2pe9qd	62	37	with	with	IN
cord-326672-0x2pe9qd	62	38	cystic	cystic	JJ
cord-326672-0x2pe9qd	62	39	fibrosis	fibrosis	NN
cord-326672-0x2pe9qd	62	40	with	with	IN
cord-326672-0x2pe9qd	62	41	a	a	DT
cord-326672-0x2pe9qd	62	42	G551D	g551d	JJ
cord-326672-0x2pe9qd	62	43	mutation	mutation	NN
cord-326672-0x2pe9qd	62	44	Efficacy	efficacy	NN
cord-326672-0x2pe9qd	62	45	and	and	CC
cord-326672-0x2pe9qd	62	46	safety	safety	NN
cord-326672-0x2pe9qd	62	47	of	of	IN
cord-326672-0x2pe9qd	62	48	the	the	DT
cord-326672-0x2pe9qd	62	49	elexacaftor	elexacaftor	NN
cord-326672-0x2pe9qd	62	50	plus	plus	CC
cord-326672-0x2pe9qd	62	51	tezacaftor	tezacaftor	NNP
cord-326672-0x2pe9qd	62	52	plus	plus	CC
cord-326672-0x2pe9qd	62	53	ivacaftor	ivacaftor	NNP
cord-326672-0x2pe9qd	62	54	combination	combination	NN
cord-326672-0x2pe9qd	62	55	regimen	regimen	NN
cord-326672-0x2pe9qd	62	56	in	in	IN
cord-326672-0x2pe9qd	62	57	people	people	NNS
cord-326672-0x2pe9qd	62	58	with	with	IN
cord-326672-0x2pe9qd	63	1	cystic	cystic	NNP
cord-326672-0x2pe9qd	63	2	fibrosis	fibrosis	NNP
cord-326672-0x2pe9qd	63	3	homozygous	homozygous	JJ
cord-326672-0x2pe9qd	63	4	for	for	IN
cord-326672-0x2pe9qd	63	5	the	the	DT
cord-326672-0x2pe9qd	63	6	F508del	F508del	NNP
cord-326672-0x2pe9qd	63	7	mutation	mutation	NN
cord-326672-0x2pe9qd	63	8	:	:	:
cord-326672-0x2pe9qd	64	1	a	a	DT
cord-326672-0x2pe9qd	64	2	double	double	JJ
cord-326672-0x2pe9qd	64	3	-	-	HYPH
cord-326672-0x2pe9qd	64	4	blind	blind	JJ
cord-326672-0x2pe9qd	64	5	,	,	,
cord-326672-0x2pe9qd	64	6	randomised	randomised	JJ
cord-326672-0x2pe9qd	64	7	,	,	,
cord-326672-0x2pe9qd	64	8	phase	phase	NN
cord-326672-0x2pe9qd	64	9	3	3	CD
cord-326672-0x2pe9qd	64	10	trial	trial	NN
cord-326672-0x2pe9qd	64	11	Elexacaftor	Elexacaftor	NNP
cord-326672-0x2pe9qd	64	12	-	-	HYPH
cord-326672-0x2pe9qd	64	13	Tezacaftor	Tezacaftor	NNP
cord-326672-0x2pe9qd	64	14	-	-	HYPH
cord-326672-0x2pe9qd	64	15	Ivacaftor	Ivacaftor	NNP
cord-326672-0x2pe9qd	64	16	for	for	IN
cord-326672-0x2pe9qd	64	17	Cystic	Cystic	NNP
cord-326672-0x2pe9qd	64	18	Fibrosis	Fibrosis	NNP
cord-326672-0x2pe9qd	64	19	with	with	IN
cord-326672-0x2pe9qd	64	20	a	a	DT
cord-326672-0x2pe9qd	64	21	Single	Single	NNP
cord-326672-0x2pe9qd	64	22	Phe508del	Phe508del	NNP
cord-326672-0x2pe9qd	64	23	Allele	Allele	NNP
cord-326672-0x2pe9qd	64	24	Lumacaftor	Lumacaftor	NNP
cord-326672-0x2pe9qd	64	25	-	-	HYPH
cord-326672-0x2pe9qd	64	26	Ivacaftor	Ivacaftor	NNP
cord-326672-0x2pe9qd	64	27	in	in	IN
cord-326672-0x2pe9qd	64	28	Patients	Patients	NNP
cord-326672-0x2pe9qd	64	29	with	with	IN
cord-326672-0x2pe9qd	64	30	Cystic	Cystic	NNP
cord-326672-0x2pe9qd	64	31	Fibrosis	Fibrosis	NNP
cord-326672-0x2pe9qd	64	32	Homozygous	Homozygous	NNP
cord-326672-0x2pe9qd	64	33	for	for	IN
cord-326672-0x2pe9qd	64	34	Phe508del	Phe508del	NNP
cord-326672-0x2pe9qd	64	35	CFTR	CFTR	NNP
cord-326672-0x2pe9qd	64	36	Tezacaftor	Tezacaftor	NNP
cord-326672-0x2pe9qd	64	37	-	-	HYPH
cord-326672-0x2pe9qd	64	38	ivacaftor	ivacaftor	NN
cord-326672-0x2pe9qd	64	39	in	in	IN
cord-326672-0x2pe9qd	64	40	patients	patient	NNS
cord-326672-0x2pe9qd	64	41	with	with	IN
cord-326672-0x2pe9qd	64	42	cystic	cystic	JJ
cord-326672-0x2pe9qd	64	43	fibrosis	fibrosis	NN
cord-326672-0x2pe9qd	64	44	homozygous	homozygous	JJ
cord-326672-0x2pe9qd	64	45	for	for	IN
cord-326672-0x2pe9qd	64	46	Phe508del	Phe508del	NNP
cord-326672-0x2pe9qd	64	47	Acronyms	Acronyms	NNPS
cord-326672-0x2pe9qd	64	48	confuse	confuse	VBP
cord-326672-0x2pe9qd	64	49	everyone	everyone	NN
cord-326672-0x2pe9qd	64	50	:	:	:
cord-326672-0x2pe9qd	64	51	combating	combat	VBG
cord-326672-0x2pe9qd	64	52	the	the	DT
cord-326672-0x2pe9qd	64	53	use	use	NN
cord-326672-0x2pe9qd	64	54	of	of	IN
cord-326672-0x2pe9qd	64	55	acronyms	acronym	NNS
cord-326672-0x2pe9qd	64	56	to	to	TO
cord-326672-0x2pe9qd	64	57	describe	describe	VB
cord-326672-0x2pe9qd	64	58	paediatric	paediatric	JJ
cord-326672-0x2pe9qd	64	59	research	research	NN
cord-326672-0x2pe9qd	64	60	studies	study	NNS